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THERAPEUTIC POTENTIAL OF RHTRAIL FOR MALIGNANT MELANOMA

KATHERINE A. TURNER

ABSTRACT
The application of recombinant human Tumor Necrosis Factor-Related ApoptosisInducing Ligand (rhTRAIL) for the treatment of cancer holds great promise due to its
ability to selectively induce apoptosis in cancer cells while not harming normal healthy
cells. This is evident by the robust levels of apoptosis induced in malignant melanoma
cells while no event of apoptosis was observed in the non-transformed counterpart of
melanomas, melanocytes. However, the clinical utility of rhTRAIL is limited due to the
heterogeneity seen in rhTRAIL-sensitivity among cancers.

rhTRAIL-resistance is

especially prevalent in cases of malignant melanoma. Melanoma rhTRAIL-resistance can
be attributed to a number of different causations including low expression of rhTRAILbinding receptors (death receptors (DRs)) and overexpression of anti-apoptotic proteins.
Most noteworthy is the correlation between rhTRAIL-sensitivity and the membrane
expression of rhTRAIL receptors DR4 and DR5. The membrane expression of DR4 and
DR5 may be potential markers for predicting a patient’s sensitivity to rhTRAIL. We
propose the development of an in vitro assay to measure the membrane expression of DR4
and DR5 to determine a patient’s suitability for rhTRAIL-treatment.

Additionally,

rhTRAIL-resistance can be circumvented by combining rhTRAIL with the “Mother
Nature”-derived compound quercetin. Quercetin possesses the ability to modulate some
of the cellular components that confer rhTRAIL-resistance.

Resistant malignant

melanomas are sensitized to the effects of rhTRAIL by the quercetin-mediated
vi

upregulation of DR4 and DR5 and the downregulation of the anti-apoptotic protein FLIP.
Overall, these data show the potential of rhTRAIL to act as a potent anti-cancer therapeutic
and methods to overcome rhTRAIL-resistance.
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CHAPTER I
INTRODUCTION
1.1 Malignant Melanoma.
Malignant melanoma is the most deadly of the skin cancers with increasing
incidence and mortality rates worldwide. Characterized by high rates of metastasis and
chemo-resistance, malignant melanoma is associated with a lifetime risk of 1 in 52. In the
U.S., 76,380 people are expected to be diagnosed with malignant melanoma resulting in
10,130 deaths and $3.3 billion spent in treatments for 2016. In its early stage, melanoma
is easily cured, but the prognosis associated with metastatic malignant melanoma remains
very poor. For localized melanoma contained to the epidermis, the 5-year survival rate is
98%. When detected early, the melanoma cells can be removed in most cases by one of
several methods such as surgical excision.

Whereas advanced cases of metastatic

malignant melanoma has an extremely low median survival rate. Once the cancer invades
the basement membrane and moves to the lymph nodes to form regional melanoma and
finally metastasizes to other organs to form distant melanoma the 5-year survival rate
decreases to 63% and 17%, respectively (1). Despite decades of clinical trials, a standard
first-line treatment for metastatic malignant melanoma has not been established and
remains one of the most treatment-refractory malignancies. Melanomas with deep tissue
1

invasion or that have metastasized may be treated with surgery, targeted therapy,
immunotherapy, chemotherapy or radiation therapy.

However, treatments with

chemotherapeutic agents, Dacarbazine and Tamoxifen, or immunotherapies with
Interleukin-2 (IL-2) or Interferon-α (INF- α) have not resulted in responses of long-lasting
remissions. Extensive research on the epidemiology of melanoma has resulted in more
effective therapies such as targeted treatments, Vernurafenib and Darbrafenib, and
immunotherapies, anti-CTLA-4 and anti-PD1 (2–4). Unfortunately, these newer therapies
have been linked with numerous negative side effects, slow effectiveness and only transient
anti-tumor activity due to acquired resistance with the emergence of resistant cells and
tumor recurrence (5,6). New strategies are needed to improve the treatment outcome and
survival of these patients

1.2 Dysregulation of Apoptosis and Cancer.
Cancer is a disease characterized by irregular proliferation, inappropriate cell
survival, decreased apoptosis, cell immortalization, invasion of surrounding tissue and
metastasis. In particular, apoptosis or programmed cell death is a tightly-controlled
physiological process of cell elimination that is essential in the maintenance of tissue
homeostasis. Dysregulation in the apoptotic pathway or resistance to apoptotic stimuli is
instrumental in the initiation and progression of cancer. Mechanisms of resistance include
overexpression of oncogenes, inactivation of tumor suppressor genes, imbalance of proand anti-apoptotic proteins and inactivation of the intrinsic and extrinsic apoptotic
pathways.

Many current cancer therapies such as conventional chemotherapy and

radiotherapy aim to eliminate cancer cells through induction of apoptosis. However,

2

induction of apoptosis only occurs secondarily as a result of causing severe cell damage in
a p53-dependent manner. The tumor suppressor gene, p53, is an important mediator
between sensors of cellular damage and the intrinsic pathway of apoptosis. However, in
over 50% of all cancers, p53 is mutated and resistance to standard p53-dependent cancer
therapies often occurs. Additionally, these traditional therapies are non-specific for cancer
cells and target all cells, cancerous and non-cancerous, for cell death. The lack of
specificity often results in systemic toxicity that effects the patients overall quality of life
and prevents optimal drug-dosing (7). The development of more selective and specific
therapies that can circumvent the resistance of chemotherapy and radiotherapy is vital. A
direct and selective therapy is the application of pro-apoptotic receptor agonists that can
induce apoptosis through the p53-independent extrinsic pathway (8).

1.3 Pathways of Apoptosis.
Apoptosis or type I programmed cell death is characterized by cell shrinkage,
chromatin condensation, nuclear fragmentation, destruction of the cytoskeleton, blebbing
of the cellular membrane and the formation of apoptotic bodies. The apoptotic bodies are
then recognized and phagocytized by macrophages without an inflammatory response (9).
The process of apoptosis can be triggered by two distinct but convergent pathways: the
death-receptor-mediated extrinsic pathway and the mitochondrial-dependent intrinsic
pathway (Fig. 1.1), both of which offer therapeutic manipulation. The extrinsic pathway
of apoptosis is triggered by the binding of pro-apoptotic death-ligands, such as TRAIL, to
receptors located on the extracellular member that possess cytoplasmic death domains
(DD). Ligand-receptor binding results in the trimerization of the receptors leading to the

3

Figure 1.1: Schematic of the extrinsic and intrinsic pathways of apoptosis. (Modified
from Duiker et al. 2006)
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assembly of the intracellular death-inducing signaling complex (DISC). At the DISC, the
adaptor protein, Fas-associated death domain (FADD), acts as a bridge between the deathreceptor complex and the pro-domain of the initiator caspase, procaspase 8. Induced
proximity results in the autoproteolytic cleavage of procaspase 8 into its active form,
caspase 8. Caspase 8 possesses the ability to activate downstream effector or executioner
caspases such as procaspases 3, 6 and 7 to caspases 3, 6 and 7, which ultimately execute
the hallmark events of apoptosis.

Moreover, tfhe mitochondrial-dependent intrinsic

pathway is initiated after DNA or microtuble damage by such agents or environmental
changes as chemotherapy, radiotherapy, hypoxia, starvation and other kinds of severe
cellular stress. This pathway is dependent on p53 and the ratio between pro-apoptotic and
anti-apoptotic members of the Bcl-2 family. When the intrinsic pathway is activated, proapoptotic members of the Bcl-2 family, Bax and Bak, will translocate to the mitochondria
causing a decrease in its membrane potential and the release of cytochrome c. Cytosolic
cytochrome c binds to the adaptor protein, apoptotic protease activating factor-1 (Apaf-1),
and procaspase 9 in the presence of dATP, forming the apoptosome signaling complex.
Formation of the apoptosome complex results in the activation of procaspase 9 to caspase
9. Activated caspase 9 can then activate the executioner procaspases 3, 6 and 7 to their
active form. Cross-talk between the extrinsic pathway and the intrinsic pathway can occur
and is mediated through Bid, a BH3-only protein of the Bcl-2 family. Caspase 8 can
activate Bid through proteolytic cleavage to truncated Bid (tBid), which then translocates
to the mitochondria, activating the intrinsic pathway. This mitochondrial amplification
loop intensifies the pro-apoptotic signal initiated by the death-receptor-mediated extrinsic
pathway and provides a mechanism to activate the intrinsic pathway independent of p53.

5

Of additional importance are proteins that inhibit the pathways of apoptosis, such as antiapoptotic members of the Bcl-2 family and inhibitors of apoptosis proteins (IAPs). Bcl-2
and Bcl-xL, members of the Bcl-2 family, prevent the activation of the intrinsic pathway
by preventing the release of cytochrome c from the mitochondria. IAPs such FLIP, XIAP,
cIAP and survivin act as anti-apoptotic proteins by inhibiting the activation of caspases
from their inactive precursors, specifically procaspase 8 and 9 (10).

1.4 TRAIL.
A member of the TNF-gene superfamily, TRAIL was discovered through sequence
homology to Fas Lignad (FasL). TRAIL is expressed as a type II transmembrane protein
possessing a highly-conserved extracellular C-terminus. The extracellular domain of the
membrane-bound TRAIL can be cleaved by metalloproteases to form soluble TRAIL
(sTRAIL) (11).

Both full-length membrane-bound TRAIL and sTRAIL can induce

apoptosis in a wide variety of human cancers, ranging from colon, lung, breast, kidney,
brain, pancreas, prostate, skin, leukemia, multiple myeloma, lymphoma and nonHodgkin’s lymphoma (NHL), independent of p53 status and with minimal toxicity toward
normal tissues both in vitro and in vivo (10). Other members of the TNF-family such as
FasL, TNFα and CD40L are also able to induce apoptosis, but their ability to be utilized as
effective cancer therapeutics is hindered by their systemic toxicity.

For example,

administration of FasL causes severe liver toxicity and systemic use induces a sepsis-like
syndrome. Whereas, TRAIL shows the ability to selectively induce apoptosis in cancer
cells with no influence on normal cells or signs of systemic toxicity (12). One study shows
the selectivity of TRAIL by testing early-passage primary human umbilical vein
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endothelial cells, lung fibroblasts, mammary, renal or prostatic epithelial cells, colon
smooth muscle cells and astrocytes with high dosages of TRAIL (1 μg/ml). These healthy
noncancerous cells were found to be unaffected by the TRAIL with no morphological
evidence of apoptosis (13). For this reason, TRAIL represents a valuable candidate as a
pro-apoptotic cancer therapy. Located on chromosome 3 at position 3q26, TRAIL mRNA
is found in a variety of cells and tissues, particularly in lymphoid system, spleen, prostate,
and lung (14). This contrasts FasL whose transcripts are largely restricted to stimulated T
cells. The ubiquitous distribution implies that TRAIL must not be toxic to most tissues.
Like other members of the TNF-family, TRAIL is involved in apoptotic signaling and in
the function of the immune system. TRAIL is found to be upregulated upon lymphocyte
activation and is expressed on the surface of natural-killer cells and cytotoxic T cells.
Additionally, sTRAIL is found to be generated by activated monocytes and neutrophils and
seems to play a role in the elimination of virus-infected or malignant cells by these immune
effector cells (11,15). The role of TRAIL in tumor immune-surveillance is displayed in
TRAIL neutralization experiments. In these experiments, carcinogen methylcholanthrene
(MCA)-mediated tumor formation was found be to more prevalent in mice where TRAIL
was neutralized and also in TRAIL-/- mice compared to wild-type (WT) mice with
functional TRAIL expression (14). Overall, it is believed that the true function of TRAIL
is in immune-surveillance functioning in innate immune responses against both tumors and
virus-infected cells (16).

7

1.5 TRAIL Structure.
Crystallographic studies show that TRAIL has a homotrimeric structure, consisting
of three TRAIL monomers coordinated by an internal zinc atom (Fig 1.2) (15). The zinc
atom is buried at the center of the trimer, coordinated by a single cysteine residue on each
monomer located at position 230 and is required for the structure and function of TRAIL.
The metal-mediated trimerization of a ligand represents a unique stscarofructure and
stability that differentiates TRAIL from all other members of the TNF-family. With a
stoichiometry of approximately one metal ion per trimer, zinc is required for maintaining
the structure and stability of the trimer and hence the overall biological activity of TRAIL.
The functional importance of the zinc-binding site is demonstrated by the observation that
alanine or serine substitutions of cysteine 230 results in 20- and 70-fold reduction in the
apoptotic activity of TRAIL, respectively. Additionally, removal of zinc from WT TRAIL
by dialysis against chelating agents results in a significant decrease in the receptor-binding
affinity of TRAIL and a 90-fold decrease in apoptotic activity. Zinc depletion results in
the destabilization of TRAIL marked by large conformational changes in the cysteine
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Figure 1.2: The molecular protein structure of TRAIL. (Ashkenzi et al. 2008)
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230 region and a 25°C decrease in the melting point compared to the WT TRAIL. Removal
of zinc makes the cysteines more prone to oxidation and to the formation of poorly active
monomers or disulfide-linked dimers of TRAIL (12).

1.6 TRAIL Receptors.
TRAIL can bind five different receptors: four membrane-bound and one soluble
(Fig 1.3). Two of the receptors, death receptor 4 (DR4) and death receptor 5 (DR5), act as
functional pro-apoptotic receptors, containing a cytoplasmic DD through which TRAIL
can initiate the extrinsic apoptotic pathway. The two other membrane-receptors, decoy
receptor 1 (DcR1) and decoy receptor 2 (DcR2), also bind TRAIL but act as antagonistic
receptors due to their lack of a DD. Therefore, these receptors cannot transmit an apoptotic
signal upon ligand binding. DcR1 is glycosylphosphatidylinositol (GPI)-linked to the cell
and is absent of any transmembrane or cytoplasmic domains capable of transmitting an
intracellular signal. DcR2 contains a truncated DD and also cannot transmit an apoptotic
signal. In addition to the four membrane-bound receptors, a fifth soluble antagonistic
receptor, osteoprotegerin (OPG) exists. When TRAIL binds a functional receptor, DR4 or
DR5, then the extrinsic apoptotic cascade will be triggered, but if TRAIL binds a decoy
receptor, then no signal will be transmitted. TRAIL binds as a homotrimer stabilized by a
zinc molecule to the cysteine-rich pseudorepeats in the extracellular domain of these
receptors causing trimerization of the receptors. The crystal structure of the ligand-receptor
complex between TRAIL and DR4 and/or DR5 shows that the trimeric ligand engages with
three monomeric receptors, interacting at the interfaces between the monomers of TRAIL

10

Figure 1.3: Schematic of the five TRAIL receptors. (Kimberley F et al. 2004)
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(Fig 1.2). This phenomenon led to the formation of the “ligand trimerization model” in
which the incoming trimeric TRAIL recruits three receptor molecules, triggering an
intracellular signaling cascade (16).

1.7 TRAIL preparations.
A recombinant version of TRAIL is utilized here, recombinant human TRAIL
(rhTRAIL). rhTRAIL is the optimized form of the endogenous apoptosis-inducing ligand,
consisting of the extracellular C-domain, amino acids 114-281, and lacks any exogenous
sequence tags. rhTRAIL, like its naturally occurring counterpart, can induce apoptosis in
a broad range of cancer cells by binding to DR4 and/or DR5. Interestingly, rhTRAIL can
induce apoptosis in cancer cells while not activating apoptosis in normal cells, including
epithelial, endothelial, fibroblastic, smooth muscle, astrocytic and hematopoietic stem
cells. Although the mechanism in which rhTRAIL is able to selectively induce apoptosis
in cancer cells while sparing normal cells is not yet been established, this characteristic
makes rhTRAIL a prime candidate as a pro-apoptotic cancer therapy (15). However, the
true potential for rhTRAIL as a therapeutic is marred by a controversial debate over its
potential toxicity to human hepatocytes (16). Certain non-optimized versions of rhTRAIL
that contain exogenous sequence tags have been reported to induce apoptosis in cultured
hepatocytes. Specifically, a polyhistidine-tagged preparation of rhTRAIL (rhTRAIL.His)
was found to induce apoptosis in human hepatocytes. Whereas the nontagged version of
rhTRAIL, even at a 1000-fold higher concentration, did not induce apoptosis in the human
hepatocytes. It was later shown that rhTRAIL.His contained low amounts of zinc and was
unstable in solution forming insoluble aggregates upon incubation.

12

The nontagged

rhTRAIL contained near-stoichiometric zinc levels and remained homogenous as 99%
trimers (17). The safety of the nontagged rhTRAIL was also proven in vivo through
intravenous (I.V.) injections into severe combined immunodeficient (SCID) mice
harboring human hepatocytes. Injection of the nontagged rhTRAIL showed no effects to
the human hepatocytes and the overall safety of the animal model was maintained (15).
The rhTRAIL presented is an optimized preparation consisting of amino acid residues 114281 and contains no exogenous sequence tags.

1.8 Preclinical and Clinical Trials of rhTRAIL.
RhTRAIL, an optimized and nontagged version, has been used in clinical studies
led by Genentech, Inc. Beforehand, a number of preclinical studies were performed to
determine the pharmacokinetics and safety of rhTRAIL. The pharmacokinetic properties
of rhTRAIL were investigated in a number of diverse animal models. The half-life of
rhTRAIL was found to be 3-5 minutes in rodents and 23-32 minutes in non-human
primates, and its clearance directly correlated with glomerular filtration rate. The half-life
was not affected by multiple dosages, and there was no evidence of drug accumulation or
antibody formation (18). Additionally, preclinical safety studies in non-human primates
such as cynomologus monkeys and chimpanzees showed that systemic application of
rhTRAIL was unlikely to cause major toxicity in human patients. Even at dosages as high
as 100 mg/kg given for seven consecutive days were well tolerated with no signs of clinical
pathology to any major organs. Most noteworthy, is that there were no detectable
indications of liver toxicity or changes in liver enzyme activity (13,17).
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The preclinical pharmacokinetic studies of rhTRAIL led to the design of an
optimized dose and schedule for rhTRAIL to be used in clinical trials. To achieve
maximum drug efficacy, one-hour I.V. infusion of rhTRAIL for five consecutive days on
a 21-day cycle was applied. Firstly, the safety and pharmacokinetics were evaluated in a
phase Ia trial in patients with advanced cancer and lymphoma and a phase I dose-escalation
study. The phase Ia trial in patients with advanced cancer and lymphoma consisted of 39
patients who received rhTRAIL at dosages ranging from 0.5-15 mg/kg I.V. for five days
on a 21-day cycle. Even dosages as high as 15 mg/kg for 120 days resulted in no drug
accumulation or antibody formation (19). The dose-escalation study consisted of 71
patients with advanced cancers who were treated with I.V. infusions of Dulanermin
(rhTRAIL) at doses between 0.5-35 mg/kg for five days on a 21-day cycle. Evaluation of
the maximum-tolerated dose and dose-limiting toxicities was done to determine the overall
safety of receiving multiple doses of rhTRAIL. Adverse effects included fatigue, nausea
and vomiting but overall the effects were mild and well managed and others were
consistent with disease progression. It was also found that rhTRAIL doses up to 35 mg/kg
were well tolerated and safe with no antibody formation or hepatotoxicity. The half-life of
rhTRAIL was found to be 0.56-1.02 hours after treatment, and there was no drug
accumulation after multiple doses. Overall, 33 (46%) of patients had stable disease or
better at the end of cycle 2. Eight patients had stable disease for >4 months but <6 months
and two patients (3%) with chondrosacroma had confirmed partial responses at >6 months
(20). Additionally, rhTRAIL was evaluated in combination with Rituximab in patients
with non-Hodgkin’s lymphoma and also in combination with Paclitaxel, Carboplatin and
Bevacizumab (PCB) in patients with advanced non-squamous non-small-cell lung cancer
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(NSCLC). In the clinical trial of rhTRAIL in combination with Rituximab, seven patients
were treated with one-hour I.V. infusion of 4 or 8 mg/kg rhTRAIL for five days on a 21day cycle and Rituximab at 375 mg/m2 weekly. There were no dose-limiting toxicities or
adverse effects to report. Two patients had a complete response, one had a partial response
and two had a stable disease response (21). Moreover, in the clinical trial of rhTRAIL in
combination with PCB, the standard treatment for non-squamous NSCLC, 24 patients were
treated with PCB on day one of the 21-day cycle and Dulanermin (rhTRAIL) at 4 or 8
mg/kg for five days or 15 or 20 mg/kg for 2 days. There were no dose-limiting toxicities
and a maximum-tolerated dose was not reached. The study concluded with an overall
response rate of 58%, with one complete response, 13 partial responses and nine patients
with a stable disease response. The median progression-free survival was 7.2 months and
one year after the trial, 10 out of 24 patients were in long-term follow-up for survival and
11 of 24 patients had died (22). In the end, the clinical trials found that only a small cohort
of patients actually responded to rhTRAIL-based therapies. Combination studies showed
that the addition of rhTRAIL to established anti-cancer therapeutics did not result in a
clinical benefit. As a result, the clinical use of rhTRAIL was terminated. However, clinical
trials still continue with monoclonal antibodies against DR4 or DR5 (23).

1.9 rhTRAIL Resistance.
Although rhTRAIL shows the ability to induce apoptosis in a broad range of human
cancer cells, the sensitivity to rhTRAIL is heterogeneous.

Some cell lines display

resistance to rhTRAIL-induced apoptosis while others can acquire resistance after repeated
exsposure.

For example, a study of eight human melanoma cell lines treated with
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increasing concentrations of rhTRAIL found that five of the lines (WM 9, WM 35, WM
98-1, WM 793 and WM 1205 Ln) were sensitive to the rhTRAIL, while three lines (WM
164, WM 1791-C and WM 3211) and normal human melanocytes were resistant (24).
Originally the varying expression of pro-apoptotic rhTRAIL receptors versus decoy
receptors was thought to be the cause for the difference in sensitivity to rhTRAIL-induced
apoptosis. However, studies have shown that receptor distribution between pro- and antiapoptotic receptors does not correlate with sensitivity (15). Current literature describes a
myriad of ways in which sensitivity to rhTRAIL may be controlled, which is often celltype dependent. One mechanism of rhTRAIL-resistance is the increased expression of
IAPs such as FLIP, XIAP, cIAP and survivin. FLIP inhibits the activation caspase 8,
stopping the extrinsic pathway at the most apical point. Evidence shows at FLIP levels are
the highest in rhTRAIL-resistant cells while being low or undetectable in rhTRAILsensitive cell lines.

Actinomycin D-mediated inhibition of FLIP resulted in the

sensitization of rhTRAIL-resistant cells (24). Additionally, the synergistic effects of 5’FU
with rhTRAIL in killing cancer cells was attributed to the downregulation of FLIP (16) .
In a study using siRNA to downregulate specific IAPs, it was found that inhibition of XIAP
and survivin were the most effective in sensitizing cells to rhTRAIL-induced apoptosis
compared to other IAPs (25). Moreover, the equilibrium between pro- and anti-apoptotic
members of the Bcl-2 family plays an important role in rhTRAIL-sensitivity.
Overexpression of anti-apoptotic proteins, Bcl-2 and Bcl-xL, correlates highly with
rhTRAIL-resistance. Transfection with vectors for increased Bcl-2 and Bcl-xL expression
resulted in rhTRAIL-resistance in rhTRAIL-sensitive cell lines (26,27). Furthermore,
inactivation of the pro-apoptotic Bcl-2 proteins, Bax and Bak, along with the Bcl-xL-
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mediated sequestering of tBID, renders cells resistant to rhTRAIL (27,28). Finally,
rhTRAIL-resistance may occur at the receptor level such as lack of pro-apoptotic receptor
expression or mutations of the functional death-receptors. Low levels of DR4 and DR5 on
the cancer cell membrane are highly associated with rhTRAIL-resistance (29). In one case,
high levels of death-receptors on the cell surface was correlated with a lack of rhTRAILsensitivity. This insensitivity was later explained by the presence of a polymorphism in
the DD of DR4, leading to an inhibition of signaling (16). Methods to overcome rhTRAILresistance is thus essential for the successful clinical application of rhTRAIL.

1.10 rhTRAIL Synergism.
Studies suggest that an increased potency against cancer cells is achieved when
rhTRAIL is administered as a combination therapy with preexisting anti-cancer drugs. An
increase in rhTRAIL-induced apoptosis was seen in co-treatments with chemotherapy,
radiotherapy and even with nontraditional therapies such as proteasome inhibitors, histone
deacetylase inhibitors and tyrosine kinase inhibitors in vitro and in vivo. The enhancement
of rhTRAIL through co-treatments was seen in human cancers such as hepatocellular,
colon, NSCLC, prostate, pancreatic, breast, sarcoma and B-cell NHL. The augmentation
of rhTRAIL was most attributed to an increase in DR5 levels, which can be upregulated in
response to DNA damage (13,16). Of special interest is the use of compounds derived
from “Mother Nature” as co-treatments for rhTRAIL. For centuries, natural products have
been used to treat various diseases due to their efficacy, safety and inexpensiveness,
compared to traditional chemotherapeutic agents that are expensive and associated with
severe negative side effects as a result of their non-specificity. Natural compounds are
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pertinent sources for rhTRAIL co-treatments due to their potent anti-cancer activity.
Firstly, a number of natural compounds are known to upregulate pro-apoptotic rhTRAILbinding receptors DR4 and DR5. Additionally, these compounds are able to downregulate
cell survival proteins and pathways. As single agents, natural compounds have the ability
to activate cancer cell apoptosis and potentiate rhTRAIL-induced apoptosis. Lastly, the
use of natural compounds as co-treatments for rhTRAIL would be successful due to their
multi-targeted anti-cancer mechanisms. When mono-targeted therapies are used, they are
less effective and resistance can occur.

However, multi-targeted compounds are

substantially more effective and less likely to cause resistance (30,31). One natural
compound of significance is the application of quercetin as a co-treatment for rhTRAILresistant malignant melanomas.

1.11 Quercetin.
Quercetin is a polyphenol classified as a flavonol based on the presence of an
oxygen-containing ring between the two benzene rings (Fig. 1.4). Quercetin is found in
wide variety of plant-derived sources ranging from onions and apples to red wine (Fig.
1.5). Dietary quercetin is ingested in the form of glycosides which are metabolized by
intestinal microflora to form free quercetin which is absorbed through the gastrointestinal
tract (32). Numerous in vitro studies have shown the potent effects of quercetin on a wide
range of cancer types ranging from breast, lung and melanoma to leukemia and
lymphomas. The anti-cancer mechanisms of quercetin are multi-targeted and include
inhibition of proliferation signal transduction pathways, reduction of inflammatory
metabolites, interaction with type II estrogen binding sites, inhibition of glycolysis, cell

18

cycle arrest, upregulation of tumor suppressor genes, inhibition of heat shock proteins and
induction of apoptosis (33). Here we are interested in the ability of quercetin to sensitize
rhTRAIL-resistant cancer cells to undergo apoptosis.

The cellular targets quercetin

interacts with make it an excellent co-treatment candidate. Firstly, quercetin has the ability
to upregulate rhTRAIL-binding receptors, DR4 and DR5 on the cancer cell membrane.
One study with colon cancer cells shows that quercetin can upregulate both DR4 and DR5
on the cancer cell membrane (34). However other studies in prostate, lung, liver and
ovarian cancers show that quercetin only upregulates DR5 through increased transcription.
Additionally, these studies find that quercetin can directly active transcription factors
CHOP and Sp1, promoting the transcription of the DR5 gene (35–38). Moreover, several
studies have demonstrated that quercetin is able to downregulate a number of
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Figure 1.4: Structure of Quercetin. (Miles et al. 2014)
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Figure 1.5: Content of Quercetin in Selected Foods. (Miles et al. 2014)
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anti-apoptotic proteins. Firstly, quercetin has been shown to promote the proteasomemediated degradation of the caspase 8 inhibitor, FLIP (38,39). Quercetin can also
downregulate the anti-apoptotic protein survivin mediated by Akt dephosphorylation
(37,40). Overall, quercetin shows significant potential to act as a sensitizer of rhTRAILresistant malignant melanomas.
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CHAPTER II
RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-RELATED
APOPTOSIS-INDUCING LIGAND SELECTIVELY INDUCES APOPTOSIS IN
MALIGNANT MELANOMA

2.1 Abstract.
Skin cancer is among the most commonly-diagnosed cancers with malignant
melanoma being associated with the highest rate of metastasis and death. In its early stage,
melanoma is easily cured, but the prognosis associated with metastatic malignant
melanoma remains very poor and is one of the most treatment-refractory malignancies.
This work was undertaken to assess the effectiveness and safety of recombinant human
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhTRAIL) as a potential
therapeutic for malignant melanoma. rhTRAIL is the optimized version of the naturallyoccurring death-ligand TRAIL. TRAIL shows cancer cell specificity through its innate
ability to induce apoptosis in a broad range of transformed human histologies while
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showing no toxicity toward normal healthy cells. Utilizing malignant melanoma A375
cells and normal human melanocytes, the efficacy and safety of rhTRAIL was determined
in vitro and in vivo through nude mice A375 xenografts. rhTRAIL induced significant
levels of apoptosis in malignant melanoma cells in vitro and at the same time did not induce
apoptosis in non-transformed melanocytes. rhTRAIL showed remarkable in vivo potency
and was able to inhibit the growth of established melanoma tumors while showing no
toxicity towards the mice model. These data suggest that rhTRAIL is a valid candidate for
the treatment of malignant melanoma, displaying significant anti-tumor activity with
sustainably less negative side effects than traditional therapies.

2.2 Introduction.
Malignant melanoma is the most deadly form of skin cancer with increasing
incidence and mortality worldwide.

In its early stage, melanoma has an excellent

prognosis, but advanced metastatic melanoma correlates with therapeutic resistance and
low survival rates (1,2). Extensive research has resulted in the generation of targeted
treatments and immunotherapies for malignant melanoma. However, their utilization is
linked with numerous negative side effects, slow effectiveness and only transient effects
due to acquired resistance. A standard first-line therapy for malignant melanoma has not
yet been established and remains one of the most treatment-refractory malignancies (3,4).
New therapeutic strategies are needed to improve the treatment outcome and survival of
malignant melanoma patients.
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Several members of the Tumor Necrosis Factor (TNF) family, including FasL, TNFα and TNF-Related Apoptosis-Inducing Ligand (TRAIL), robustly induce apoptosis in
transformed cancer cells (5). However, the therapeutic potential of FasL and TNF-α is
hindered by their toxicity upon systemic administration. In contrast, TRAIL selectively
induces apoptosis in cancer cells. Even at supraphysiological concentrations, TRAIL
shows minimal toxicity to healthy non-transformed cells (6,7). TRAIL acts as a proapoptotic ligand through its interactions with extracellular death receptors (DR) DR4 and
DR5 (8). Binding of TRAIL to DR4 and/or DR5 initiates the extrinsic pathway of
apoptosis characterized by the cleavage of procaspase 8 to caspase 8 followed by the
activation of downstream executioner caspases 3, 6 and 7. TRAIL can also indirectly
activate the intrinsic apoptotic pathway through the caspase 8-mediated cleavage of Bid to
truncated Bid (tBid). tBid then stimulates the mitochondrial release of cytochrome c
resulting in activation of caspase 9 followed caspases 3, 6 and 7 and the hallmark events
of apoptosis (9,10).

In the present study we test a recombinant version of TRAIL, recombinant human
TRAIL (rhTRAIL). An optimized form of the apoptosis-inducing portion of the protein,
rhTRAIL consists of the extracellular C-domain amino acids 114-281 and lacks any
exogenous sequence tags. Clinical trials performed with rhTRAIL demonstrate the safety
and tolerability of rhTRAIL. Adverse effects included fatigue, nausea and vomiting, but
overall, the effects were mild and well tolerated. The half-life of rhTRAIL was 0.56-1.02
hours with no drug accumulation, antibody formation or hepatotoxicity after receiving
multiple doses. The anti-tumorigenic effects of rhTRAIL as a single agent were limited
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when given to patients with advanced cancer.

Few patients showed partial tumor

regression while most patients experienced disease progression (11,12). However, when
rhTRAIL was given in combination with other anti-cancer therapies the majority of
patients responded with complete tumor regression (13,14).

Herein we assessed the potential of rhTRAIL for the treatment of malignant
melanoma. With no standard protocol for the treatment of malignant melanoma, rhTRAIL
is an excellent candidate due to its selective toxicity towards cancerous cells only. Thus
treatment with rhTRAIL will result in maximum anti-tumor effects with decreased negative
impact on patients. We aimed to determine the effectiveness of rhTRAIL to act as a cancer
cell-specific pro-apoptotic molecule in vitro utilizing malignant melanoma A375 cells and
human melanocytes. A375 xenografts were employed to test the in vivo efficacy of
rhTRAIL to inhibit the growth of established tumors while showing no toxicity towards
the mice model. Overall, these data show the potential of rhTRAIL as a viable candidate
for the treatment of malignant melanoma.

2.3 Methods.
A. Drugs and Chemicals. Recombinant human Tumor Necrosis Factor-Related
Apoptosis-Inducing Ligand (rhTRAIL) was produced according to well defined
and previously detailed protocols (40,41,42). Briefly, rhTRAIL was produced in
E.Coli using an optimized cDNA for the particular strain used. Following induction
for 22h, the cell paste was harvested and rhTRAIL was purified stepwise by FPLC
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using previously described methods. rhTRAIL was purified to homogeneity and
analyzed at each step by SDS-PAGE following staining with Coomassie. The final
product was found to be > 99% pure as demonstrated by HPLC and mass
spectrometry.
B. Cell Culture. Human adult primary epidermal melanocytes (ATCC PCS-200-013)
were maintained in Dermal Cell Basal Medium (ATCC PCS-200-030)
supplemented with Adult Melanocyte Growth kit (ATCC PCS-200-042) and 1%
Antibiotic/Antimycotic Solution (10,000 IU/ml penicillin, 10 mg/ml streptomycin
and 25 μg/ml amphotericin). A375 cells were maintained in DMEM, supplemented
with 10% Fetal Bovine Serum (FBS) and 1% Antibiotic/Antimycotic Solution.
Cells were incubated in a 90% humidified atmosphere with 5% CO2 at 37⁰C.
C. Apoptosis Assay. Treated cells were trypsinized, harvested, washed twice with
cold PBS and resuspended in 100 μl of Annexin-V binding buffer at a concentration
of 1x103 cells/μl. According to manufacturer’s protocol, cells were incubated with
5 μl of FITC-Annexin-V and Propidium Iodide (PI) for 15 minutes at room
temperature in the dark (FITC-Annexin-V Kit Apoptosis Detection Kit I, BD
Pharminogen). Stained cells were analyzed on BDFACS Canto II using Diva
software. Single color controls (Annexin-V or PI only) were used to set up
compensation and quadrants for FACS.
D. Western Blot Analysis. Total cell lysates were prepared using RIPA lysis buffer
(Sigma) containing 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and 50 mM Tris, pH 8.0 plus a
1x cocktail of protease inhibitors (Protease Inhibitor Cocktail Set I, Calbiochem).
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Cells were lysed for 30 minutes at 4°C followed by centrifugation for 10 minutes
at 10,000 rpm at 4°C. Protein concentrations were determined using BCA protein
assay (Pierce). A 35 μg protein aliquot was mixed with 4x Laemmli’s SDS sample
buffer (0.02% Bromophenol Blue (BPB), 8% Beta-mercaptoethanol (BME), 8%
SDS, 40% glycerol and 250 mM Tris-HCl, pH 6.8). Cell lysates were heated for
five minutes at 100°C, resolved by 12% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. The
membrane was blocked with 5% non-fat milk or 5% BSA for ≥1 hour and incubated
with primary antibodies for PARP, caspase 8, caspase 3, Bid, caspase 9, caspase 6,
caspase 7 (Cell Signaling). After incubation, the membrane was incubated with
secondary anti-rabbit or mouse horseradish peroxidase (HRP)-conjugated
antibodies (Biorad). Proteins were visualized through development by enhanced
chemiluminescence (ECL 2 Western Blotting Substrate, Pierce) and exposure on
X-ray film. The blots were reprobed for β-actin to confirm equal protein loading.
E. Cytochrome c Release. Cells were resuspended in permeabilization buffer (400
µg/mL digitonin, 75 mM KCl, 1mM NaH2PO4, 8 mM Na2HPO4 and 250 mM
sucrose) plus protease inhibitors. Samples were incubated for 10 minutes at 4°C,
centrifuged at 16,000 g for five minutes at 4°C and the supernatants were kept as
the cytosolic fraction. Samples were quantified as described above and 60 μg was
resolved on a 15% gel. As described above, the gel was transferred to PVDF,
blocked and incubated with anti-cytochrome c (Cell Signaling) and visualized by
chemiluminescence.
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F. Death Receptor Membrane Expression.

Treated cells were collected with

enzyme-free PBS-based cell dissociation buffer (Gibco Life Technologies) and
stained with mouse anti-human DR4 and DR5 conjugated to phycoerythrin (PE)
(eBioscience). Briefly, 0.25x106 cells were incubated in 100 µl of staining buffer
(2% FBS, 0.02% sodium azide in PBS) and 5 µl anti-DR4 or anti-DR5 for one hour
on ice in the dark. As a negative control, cells were stained with mouse IgG1κ
isotype antibody under the same conditions. After incubation, cells were washed
twice with staining buffer and resuspended in 500 µl of staining buffer and analyzed
on BD FACS Canto II using FACS Diva software.
G. Xenografts. Animal experiments were performed in accordance with guidelines
approved by the Institutional Animal Care and Use Committee (IACUC) at the
Cleveland Clinic Foundation. Female athymic nu/nu mice (Taconic Farms, Inc.)
supplement with 100 mg/l ZnCl2 water were inoculated with 1.6x106 A375 cells
subcutaneously in both flanks. Tumor volume was monitored until tumors reached
approximately 200 mm3. Tumor dimensions were measured using calipers and
tumor volume was calculated using the formula for a prolate spheroid (V=4/3πa2b,
where a=minor radius and b=major radius of the tumor) three times a week. Upon
formation of established tumors, mice were randomized into groups (n=8).
rhTRAIL-treated mice received 32 mg/kg for five days on a 21-day cycle and
vehicle-treated controls received 250 µL PBS on the same cycle intraperitoneally
(ip). The physical status of the mice, weight and activity, were visually monitored
and treatments continued until the mice reached their end point and were sacrificed
in accordance with IACUC.
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H. Immunohistochemistry. Tumors were subjected to TUNEL Staining (ApopTag
Plus Florescein In Situ Apoptosis Detection Kit, Millipore) according to
manufacturer’s protocol. Briefly, tumors were fixed in 10% formalin, treated with
protein kinase K, washed twice with PBS, incubated in equilibration buffer for 10
minutes and incubated with terminal deoxynucleotidyl transferase for 60 minutes
at 37°C. Cells were washed with stop buffer for 10 minutes and then incubated
with antidigoxigenin conjugate for 30 minutes at 25°C. After washing in PBS, cells
were mounted with DAPI and viewed on a fluorescent microscope.
I. Xenograft Histology. Following euthanasia, liver, kidney, spleen, and tumors
were harvested and fixed in 10% neutral buffered formalin. Sections of tumors and
organs were stained with H&E and viewed microscopically.
J. Statistical Analysis. Student t-test was used to determined significance. P values
less than 0.05 were deemed significant.

2.4 Results.
rhTRAIL sensitivity in vitro. Malignant melanoma A375 cells and adult human
melanocytes were tested for their sensitivity to rhTRAIL-induced apoptosis in vitro. Cells
were treated with increasing concentrations of rhTRAIL ranging from 5 ng/ml to 1 µg/ml
for 72 hours in full medium. Levels of rhTRAIL-induced apoptosis were determined by
FITC-Annexin-V and PI staining followed by FACS analysis. A375 cells showed a dosedependent induction of apoptosis in response to rhTRAIL marked by the increasing
formation of Annexin-V+ and/or Annexin-V+ and PI+ cells (Fig. 1A&B). rhTRAIL was
able to induce apoptosis even at the lowest tested rhTRAIL concentration of 5 ng/ml with
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9.7±1.0% apoptotic cells (P<0.02), increasing to 44.6±0.5% apoptotic cells (P<0.02) in the
highest treated group of 1 µg/ml. In contrast, human melanocytes were completely
insensitive to rhTRAIL-induced apoptosis (Fig. 1A&C). Treatment with rhTRAIL, even
at the highest tested treatment concentration of 1 µg/ml of rhTRAIL, did not result in the
formation of apoptotic cells as indicated by the lack of Annexin-V+ and/or Annexin-V+ and
PI+ cells as compared to the control (P>0.05).
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Figure 2.1. rhTRAIL sensitivity in vitro. Sensitivity of A375 and melanocytes to
rhTRAIL-induced apoptosis. A) Average of three independent assays ± SEM. B)
Representative histogram of A375. C) Representative histogram of melanocytes. Lower
left quadrant: Viable cells (Annexin-/PI-), Lower right quadrant: Early apoptotic cells
(Annexin+/PI-), Upper right quadrant: Late apoptotic cells (Annexin+/PI+).
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Mechanism of rhTRAIL-initiated apoptosis. To further examine the pathway of
apoptosis induced by rhTRAIL western blotting was employed using antibodies to various
components of the apoptosis cascade.

As described above A375 cells and human

melanocytes were treated with increasing concentrations of rhTRAIL for 72 hours,
collected and whole cell lysates were revolved by SDS-PAGE and subjected to western
blotting. rhTRAIL significantly induced apoptosis in A375 noted by the fragmentation of
the DNA repair enzyme Poly-(ADP) Ribose Polymerase (PARP), starting at 10 ng/ml
rhTRAIL (Fig. 2A). Treatment with rhTRAIL was able to effectively initiate the extrinsic
pathway of apoptosis in A375 as indicated by the cleavage of procaspase 8 to caspase 8.
Additionally, rhTRAIL was able to indirectly initiate the intrinsic (mitochondrial) pathway
of apoptosis through the caspase 8-mediated cleavage of Bid, as demonstrated by the
release of cytochrome c from the mitochondria into the cytosol and the activation of
caspase 9.

Lastly, executioner caspase 3 was activated, whereas, other executioner

caspases 6 and 7 were not activated through treatment with rhTRAIL. Adult human
melanocytes were completely resistant to rhTRAIL-induced apoptosis and did not show
PARP cleavage or activation of any other proteins in the apoptotic pathways (Fig. 2B).
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Figure 2.2. Western blot analysis of apoptosis-related proteins. A) A375 and B)
Melanocytes ± rhTRAIL subjected to western blot analysis and probed with anti-PARP,
caspase 8, Bid, cytochrome c, caspase 9, caspase 3, caspase 6 and caspase 7. β-actin was
used as a loading control for each membrane. Representative β-actin is depicted.
Western blots were done in duplicates.
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Death Receptor Expression. To explain the mechanism of rhTRAIL-selectivity,
the membrane expression of DR4 and DR5 were measured on A375 cells and melanocytes
through staining with fluorescent antibodies to DR4 and DR5 followed by FACS analysis.
Overall, malignant A375 cells had significantly higher expression of both DR4 and DR5
(Fig. 3). Comparing the membrane expression of DR4, A375 cells had significantly higher
levels with a mean fluorescence intensity (MFI) of 70.3.8±7.3 compared to melanocytes
with a MFI of 33.3±1.5 (P<0.01) (Fig. 3A). For DR5, A375 cells had a higher level of
membrane expression with a MFI of 1591.3±66.9 compared with melanocytes with a MFI
of 758.0±7.5 (P<0.01) (Fig. 3B).
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Figure 2.3. Death Receptor Expression. Membrane expression of rhTRAIL-binding
receptors DR4 and DR5. Mean Fluorescent Intensity (MFI) ± SEM. Average of three
independent assays. A) A375 B) Melanocytes.
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Anti-tumorigenic effects of rhTRAIL in vivo. To test the in vivo efficacy of
rhTRAIL we further employed nude mice xenografts. Female athymic nu/nu mice were
inoculated with 1.6x106 A375 cells subcutaneously in both flanks and allowed to grow
established tumors (~200 mm3). Treatment began on day 18 with the rhTRAIL-treated
group (n=8) receiving 32 mg/kg rhTRAIL for five days on a 21-day cycle. Control mice
(n=8) received the vehicle of PBS on the same schedule. All mice were supplemented with
100 mg/l ZnCl2 in the water daily and tumor volume was measured three times a week. At
the death of the first mouse in the control group at day 29, mice treated with rhTRAIL had
an average tumor size of 585.9±232.6 mm3 while the control mice had an average tumor
size of 2055.3±476.8 mm3 (Fig. 4A). rhTRAIL-treated mice had 71.5% less tumor growth
than the vehicle-treated controls (P<0.02) (Fig. 4B). Additionally, the survival rate of the
mice was significantly enhanced following treatment with rhTRAIL compared to the
control (Fig. 4C). For the control group, all mice had to be sacrificed by day 35 due to
extremely large tumor size; however, in the rhTRAIL group 100% of the mice survived to
day 43, 75% to day 57 and one mouse lived until day 178. As compared to the control,
rhTRAIL-treated mice maintained their weight, activity and exhibited no adverse side
effects as determined by visual inspection.
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Figure 2.4. Anti-tumor activity of rhTRAIL. Sensitivity of A375 to rhTRAIL in vivo.
Treatment began day 18. rhTRAIL-mice received 32 mg/kg and control mice received
PBS ip for five days on a 21-day cycle. A) Tumor growth curve. B) End point tumor
volume. C) Survival rate.
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Xenograft histology. Tumors and major organs of sacrificed mice were collected
and analyzed. TUNEL staining of the tumors revealed significant induction of apoptosis
in the rhTRAIL-treated tumors compared to the control mice (Fig. 5A&B). Control tumors
had 0.3±0.1% TUNEL positive cells relative to DAPI stained cells compared to the
rhTRAIL-treated tumors which had 52.3±5.7% TUNEL positive cells relative to DAPI
stained cells (P<0.00001). H&E staining was also performed on the harvested tumors (Fig.
5C). rhTRAIL-treated tumors showed signs of apoptosis evidenced by the presence of
irregularly shaped and condensed nuclei compared to the control tumors possessing nicely
defined nuclei. Finally, major organs, liver, kidney and spleen, were harvested and
analyzed by H&E staining (Fig. 5C). Compared to the control, the rhTRAIL-treated organs
were healthy and showed no signs of any rhTRAIL-induced toxicity.
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Figure 2.5. Xenograft tumor and organ analysis. A) TUNEL staining of harvested
tumors. Representative picture, 20x. B) Percent TUNEL positive cells relative to DAPI
positive cells ± SEM. Values represent the average of three tumors. C) H&E staining of
tumors and major organs. Representative pictures, 20x and 40x
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2.5 Discussion.
rhTRAIL shows great promise as a pro-apoptotic anti-cancer therapeutic,
possessing the ability to selectively target and induce apoptosis in a wide variety of human
cancers ranging from solid tumors such as colon, lung and breast to hematological cancers
such as leukemia and lymphoma. At the same time, rhTRAIL does not activate apoptosis
in normal cells including endothelial, astrocytes and hematopoietic stem cells (15,16).
Currently, advanced cases of malignant melanoma are one of the leading causes of death
worldwide with no effective treatment option. Here we analyze rhTRAIL as a potential
anti-melanoma therapeutic.

These data shows that rhTRAIL is highly efficient in

selectively killing malignant melanoma cells while demonstrating no toxicity towards nontransformed melanocytes. The hallmark events of apoptosis, generation of apoptotic cells
(Annexin-V+) (17) and the fragmentation of the DNA repair enzyme PARP (18), occurred
in A375 cells but not in normal melanocytes. rhTRAIL initiates the extrinsic pathway of
apoptosis through the binding of DR4 and DR5 (19). We show that rhTRAIL is extremely
effective in directly activating the extrinsic pathway of apoptosis apparent by the robust
activation of caspase 8 in melanoma cells but not in normal melanocytes. At the highest
dose of rhTRAIL nearly all procaspase 8 is converted to caspase 8, revealing the high
affinity of rhTRAIL for DR4 and DR5 in melanoma cells. The difference in rhTRAILsensitivity between cancer cells and normal cells may lie in their membrane expression of
DRs (20,21). Examination of the membrane expression of DR4 and DR5 showed that
melanocytes have 2-fold less membrane expression of both DR4 and DR5 as compared to
malignant melanoma A375 cells. The decreased expression of DRs may explain why
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rhTRAIL does not harm normal cells and is well suited and safe for systemic administration
as an anti-cancer therapeutic with low side effects for patients.

There is crosstalk between the extrinsic and intrinsic pathways of apoptosis
mediated by the cleavage of Bid to tBid. tBid translocates to the mitochondria and initiates
the intrinsic pathway by promoting the release of cytochrome c into the cytosol. This
mitochondrial amplification loop intensifies the pro-apoptotic signal initiated by the
rhTRAIL-activated extrinsic pathway, resulting in enhanced apoptosis compared to either
pathway alone (22). Initiation of the intrinsic pathway typically occurs through activation
of p53 in response to cellular stresses such as DNA damage. This is the mechanism by
which many chemotherapeutic agents and ionizing radiation kill malignant cells. However,
in over 50% of all cancers, p53 is mutated and resistance to standard p53-dependent cancer
therapies often occurs (23). As a result of defective p53 in cancerous cells, traditional
therapies often result in severe systemic toxicity by destroying normal cells possessing the
functional form of p53, causing numerous side effects that negatively influence the
patient’s quality of life and prevent optimal drug-dosing (24). However, we show that
rhTRAIL can indirectly activate the intrinsic pathway of apoptosis and bypass the need for
p53. Therefore, the application of rhTRAIL for the treatment of cancer can be used for
any tumor type regardless of its p53 status. Additionally, the anti-tumorigenic effects of
rhTRAIL are superior over traditional therapies due to the potential activation of both the
extrinsic and intrinsic pathways of apoptosis with significantly less negative impact on the
patient.
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In clinical trials, patients with advanced cancers were treated with rhTRAIL alone
or in combination with other therapies such as Rituximab in non-Hodgkin’s lymphoma or
in combination with Paclitaxel, Carboplatin and Bevacizumab (PCB) in advanced nonsquamous non-small-cell lung cancer (NSCLC). rhTRAIL was given at doses ranging
from 0.5-35.0 mg/kg I.V. for five days on a 21-day cycle (11,12,13,14). To test the in vivo
efficacy of rhTRAIL, nude mice A375 xenografts modeled after clinical trials were
employed and mice were treated with 32 mg/kg rhTRAIL ip for five days on a 21-day
cycle. Crystallographic studies show that TRAIL has a homotrimeric structure, consisting
of three TRAIL monomers coordinated by an internal zinc atom. The zinc atom is buried
at the center of the trimer, coordinated by a single cysteine residue on each monomer and
is required for maintaining the structure, stability and the overall biological activity of
TRAIL. It has been repetitively demonstrated that zinc is necessary and required for the
optimal physiological function of TRAIL. Reports indicate that preparations of rhTRAIL
lacking adequate zinc concentrations are associated with decreased apoptotic activity
(25,26). To enhance the bioactivity of rhTRAIL in vivo, ZnCl2 was continuously provided
in the drinking water of the mice. Presented here is a novel methodology of adding of
ZnCl2 to the drinking water of mice in a pre-clinical in vivo rhTRAIL experiment. Under
these conditions, rhTRAIL showed great in vivo efficacy and was able to inhibit the growth
of established tumors while being safe and nontoxic to the mice model. As compared to
the controls, rhTRAIL-treated mice had 71.5% less tumor growth. Upon starting rhTRAIL
treatment, tumor growth leveled off; whereas, tumors of control mice grew exponentially
over time. The in vivo anti-tumor effects of rhTRAIL where confirmed in a second A375
xenograft experiment in which the drinking water of the mice was also supplemented with
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ZnCl2. At the death of the first control mouse, rhTRAIL-treated mice had 68.0% less tumor
growth than the control mice (P<0.01) (data not shown). Additionally, rhTRAIL was able
to significantly prolong the survival of the cancer-bearing mice. Specifically, by day 35
all the control mice had to be sacrificed due to extremely large tumor volume. In contrast,
100% of the mice in the rhTRAIL group survived to day 43 and one mouse lived until day
178. The fact that a mouse lived until day 178 without any further treatment is quite
significant because it had large tumors that were eliminated during rhTRAIL-treatment and
did not regrow after the treatment had ended.

The mechanism of rhTRAIL-mediated tumor growth inhibition was established in
the mice. Intra-tumor apoptosis was confirmed through TUNEL staining which identifies
apoptotic cells (27). TUNEL staining revealed significantly high levels of apoptotic cells
(TUNEL+) in the rhTRAIL-treated tumors compared to the controls. Additionally, H&E
staining of the tumors showed irregularly shaped and condensed nuclei in the rhTRAILtreated tumors, indicative of induction of apoptosis (28). Together, the H&E and TUNEL
staining show that inhibition of tumor growth within the rhTRAIL-treated A375 xenografts
was due to rhTRAIL-induced apoptosis. Lastly, upon sacrifice of the mice, major organs,
liver, kidney and spleen, were harvested and analyzed by H&E staining. Compared to the
control, rhTRAIL-treated mice showed no signs of systemic toxicity to any of the major
organs analyzed. In addition, rhTRAIL-treated mice were active, alert and they maintained
their weight as compared to the control. The histological analysis together with the
physical appearance of the rhTRAIL-treated mice confirm that although rhTRAIL is
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extremely effective at inhibiting tumor growth it is still safe and well tolerated upon
systemic administration.

The only previously reported rhTRAIL-treated A375 xenograft shows that when
treating mice at 50 mg/kg every other day tumor growth was not inhibited as compared the
control (29). However, we show that rhTRAIL is able to significantly suppress tumor
growth demonstrating of the superiority of our optimized rhTRAIL molecule.

The

previous xenograft experiment began their treatment two days after the A375 cells were
inoculated and before the establishment of a substantial tumor. Whereas in our experiment,
rhTRAIL-treatment began on day 18 when established tumors, approximately 200 mm3 in
size, were formed. rhTRAIL was given to mice with established tumors to best model
clinical settings and to see if rhTRAIL can eliminate established tumors. In the previous
experiment, even at much higher concentrations of rhTRAIL, tumor growth was not
impeded and was unable to stop the formation of A375 xenograft tumors. With our
rhTRAIL, we were able to stop the growth of already growing tumors and significantly
eliminate the tumor load on the cancer-bearing mice. Additionally, extra zinc was not
provided in the drinking water of the mice in the previous experiment. The addition of
ZnCl2 may account for the success of the presented A375 xenograft compared to the
previous study, since saturating amounts of zinc are needed for the optimal activity of
rhTRAIL (25,26). This may reveal the need to supplement patients receiving rhTRAIL
with extra zinc to increase the in vivo efficiency of rhTRAIL. Lastly, in the previous
experiment, rhTRAIL was given every other day and caused no impact on tumor growth.
However, we administered rhTRAIL every day for five days on a 21-day cycle and tumor
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growth was successfully hindered. Although rhTRAIL only has a half-life of about an
hour, it is still able to substantially inhibit tumor growth in rhTRAIL-sensitive cancer cells.
The success of our experiment shows the importance of treating everyday with rhTRAIL
for it to be most effective.

Although rhTRAIL shows the ability to induce apoptosis in a broad range of human
cancers, rhTRAIL-sensitivity is heterogeneous. Some cell lines display resistance to
rhTRAIL-induced apoptosis while others can acquire resistance after repeated exposure
(30). For example, a study of eight human melanoma cell lines treated with increasing
concentrations of rhTRAIL found that five of the lines were sensitive to rhTRAIL, while
three lines were resistant (31). Current literature describes a myriad of ways in which
sensitivity to rhTRAIL may be controlled, which is often cell-dependent. One mechanism
of rhTRAIL-resistance is the increased expression of inhibitor of apoptosis proteins (IAPs)
such as FLIP, XIAP, cIAP and survivin (32). Moreover, the equilibrium between pro- and
anti-apoptotic members of the Bcl-2 family plays an important role in rhTRAIL-sensitivity.
Overexpression of anti-apoptotic proteins Bcl-2 and Bcl-xL correlate with rhTRAILresistance along with downregulation of pro-apoptotic proteins Bax and Bak (33). Finally,
rhTRAIL-resistance may occur because of the lack of an optimum concentration of
rhTRAIL-binding receptors. Low expression levels or mutations in the rhTRAIL-binding
region of the DRs have been associated with rhTRAIL-resistance (6). Studies suggest that
an increased potency against cancer cells is achieved when rhTRAIL is administered as a
combination therapy.

An increase in rhTRAIL-induced apoptosis was seen in co-

treatments with chemotherapy, radiotherapy, irradiation and even with nontraditional
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therapies such as proteasome inhibitors, histone deacetylase inhibitors and the tyrosine
kinase inhibitor in vitro and in vivo (16). A successful co-treatment is one in which antiapoptotic proteins such as FLIP and XIAP are downregulated or DRs can be upregulated
on the membrane of the cancer cell (34,35). By combining rhTRAIL with compounds that
are able to reverse the cellular mechanisms of rhTRAIL-resistance, cancer cells that were
once resistant to rhTRAIL-induced apoptosis can now be sensitized (36).

rhTRAIL remains an attractive candidate as an anti-cancer therapy because it is
able to selectively induce apoptosis in cancer cells while not harming normal healthy cells
(37). In the present work we show that rhTRAIL induces apoptosis in vitro and in vivo in
malignant melanoma A375 cells. Our data demonstrates that rhTRAIL can induce high
levels of apoptosis through direct activation of the extrinsic pathway and the indirect
activation of the intrinsic pathway. We have validated the specificity and safety of
rhTRAIL towards normal cells. rhTRAIL was able to induce robust levels of apoptosis
malignant melanoma cells but not in normal adult human melanocytes. These data
demonstrate the specificity of rhTRAIL for transformed cells. The ability of rhTRAIL to
exhibit significant anti-tumor activity without harming normal cells contrasts traditional
chemotherapies where all cells, normal and cancerous, are targeted for cell death (38,39).
Therefore, development of anti-cancer agents such as rhTRAIL that specifically target
cancer cells is essential to enhance the treatment and overall quality of life for cancer
patients. In conclusion, these data show that rhTRAIL would be an effective treatment for
malignant melanoma with little potential for negative side effects. Thus, treatment with
rhTRAIL would fulfill the need for a potent and safe treatment option for malignant
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melanoma resulting in maximum anti-tumor effects with decreased negative impact on
patients’ lives.
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CHAPTER III
DEATH RECEPTORS AS MARKERS FOR RHTRAIL-SENSITIVITY

3.1 Abstract.
Personalized cancer treatments can be applied to the clinical use of recombinant
human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhTRAIL). rhTRAIL
holds great promise due to its selectivity for cancer cells. However, rhTRAIL clinical trials
were conducted without the screening of patients’ tumors for rhTRAIL-binding receptors
DR4 and DR5 and the unselected treatment resulted in a lack of clinical benefit. Here we
propose an in vitro test to analyze tumor cells isolated from patients for the membrane
expression of DRs to determine their suitability for rhTRAIL-treatment. Utilizing a panel
of advanced malignant melanoma cell lines, the correlation between DR membrane
expression and rhTRAIL-sensitivity was evaluated. The membrane expression of DR4 and
DR5 was examined through staining with anti-DR4 and DR5 followed by FACS.
rhTRAIL-sensitivity was determine through Annexin-V and PI staining and western
blotting post rhTRAIL-treatment.

Here we show a direct correlation between the

membrane expression of DRs and rhTRAIL-sensitivity. rhTRAIL-sensitive melanoma
lines on average had nearly four-fold more DR4 and over two-fold more DR5 than
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rhTRAIL-resistant lines. For a cancer cell to display rhTRAIL-sensitivity the optimum
expression of DRs is essential. To overcome the apoptotic threshold cancer cells must
express DRs over two-fold higher than their benign counterpart. These data show the
potential of this flow cytometry-based assay for the analysis of isolated tumor cells for DR
membrane expression. By first determining a patient’s susceptibility to rhTRAIL-based
treatments, they can be more appropriately placed in rhTRAIL-clinical trials and improve
rhTRAIL as an anti-cancer therapeutic.

3.2 Introduction.
The molecular characterization of tumors allows for the application of appropriate
anti-cancer treatments tailored to a particular patient. Personalized cancer treatments are
critical to customize therapies to individuals resulting in increased effectiveness while
minimizing negative side effects (1). Individualized cancer plans can be applied to the
clinical utilization of recombinant human Tumor Necrosis Factor-Related ApoptosisInducing Ligand (rhTRAIL) as an anti-cancer therapeutic. The development of a test to
identify patients that would benefit from rhTRAIL-based treatments is key to the successful
clinical application of rhTRAIL.

rhTRAIL is the optimized form of the cytokine TRAIL consisting of only the
biologically active C-domain (2). TRAIL is expressed by a number of immune effector
cells such as monocytes and natural killer cells and is essential in regulating homeostasis
through induction of apoptosis of aberrant cells (3). The application of rhTRAIL as an
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anti-cancer therapy shows great promise due to its ability to selectively induce apoptosis
in a broad range of tumor types while showing minimal toxicity to normal non-transformed
cells. The mechanism of cancer cell specific rhTRAIL-induced apoptosis is through the
binding of two pro-apoptotic death receptors (DRs), DR4 and DR5 that are more
abundantly expressed on cancer cells compared to normal healthy cells (4–6). Binding of
rhTRAIL to DR4 and/or DR5 initiates the extrinsic pathway of apoptosis characterized by
an intracellular caspase cascade involving the proteolytic cleavage of pro-enzymes into
their activate form. At the end of the cascade, executioner caspases are activated and carry
out the hallmark events of apoptosis including DNA fragmentation, cell shrinkage and
cytoplasmic budding into apoptotic bodies (7,8).

The application of rhTRAIL as an anti-cancer therapeutic has been a rocky “trail”.
Pre-clinical studies were successful, showing the potent pro-apoptotic activity of rhTRAIL
to a wide variety of human cancers both solid and hematological in vitro and in vivo (9).
The human pharmacokinetics and tolerability of rhTRAIL were evaluated in phase Ia trials
and displayed the safety of rhTRAIL with no toxicity to normal healthy cells with a halflife of approximately one hour (10,11). However, when rhTRAIL entered phase Ib/II trials,
alone and in combination with established cancer therapeutics, the anti-tumorigenic effects
of rhTRAIL were low and only a small cohort of patients responded to rhTRAIL-therapy
while the majority of patients were resistant and experienced disease progression. As a
result of the low efficacy and short half-life, the clinical use of rhTRAIL has been
discontinued (12).
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rhTRAIL-resistance can be attributed to multitude of different sources but
expression of rhTRAIL-binding receptors DR4 and DR5 is a major regulatory point for
rhTRAIL-sensitivity. Located at the most apical part of the rhTRAIL-induced apoptotic
pathway, multiple reports claim that rhTRAIL-resistance is associated with the decreased
expression of DRs on the cancer cell membrane (13,14). Consequently, the membrane
expression of DR4 and DR5 may be potential markers for predicting a patient’s sensitivity
to rhTRAIL and therefore discriminate which patients would benefit from rhTRAILtherapy from those who will not. We propose the development of an in vitro test to analyze
isolated tumor cells for their membrane expression of DR4 and DR5 in order to determine
a patient’s suitability for rhTRAIL-treatment. Here we test the value of measuring the
membrane expression DR4 and DR5 by flow cytometry on a panel of advanced metastatic
malignant melanoma cell lines as a prospective marker for rhTRAIL-sensitivity.

3.3 Methods.
A. Drugs and Chemicals. Recombinant human Tumor Necrosis Factor-Related
Apoptosis-Inducing Ligand (rhTRAIL) was produced according to well defined
and previously detailed protocols (15–17).
B. Cell Culture. Cells were incubated in a 90% humidified atmosphere with 5% CO2
at 37⁰C. Human adult primary epidermal melanocytes (ATCC PCS-200-013) were
maintained in Dermal Cell Basal Medium supplemented with an Adult Melanocyte
Growth kit (ATCC PCS-200-042) and 1% Antibiotic/Antimycotic Solution. The
malignant melanoma cell lines, A375 (ATCC CRL-1619), WM9 and WM164 were
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maintained in DMEM and MeWo (ATCC HTB-65) was maintained in RPMI, both
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Antibiotic/Antimycotic
Solution. WM9 and WM164 were a kind gift from Dr. Daniel J. Lindner from the
Cleveland Clinic Foundation, Cleveland, OH. Malignant melanoma lines are
derived from patient tumors. A375 was derived from an epithelial skin biopsy.
MeWo, WM9 and WM164 are metastatic malignant melanomas isolated from the
lymph nodes.
C. Death Receptor Membrane Expression. Untreated and rhTRAIL-treated cells
were collected with enzyme-free phosphate-buffered saline (PBS)-based cell
dissociation buffer (Gibco Life Technologies) and stained with mouse anti-human
DR4 or DR5 conjugated to phycoerythrin (PE) (eBioscience). Briefly, 0.25x106
cells were incubated in 100 µl of staining buffer (2% FBS and 0.02% sodium azide
in PBS) and 5 µl anti-DR4 or anti-DR5 for one hour on ice in the dark. As a
negative control to account for non-specific antibody binding, all four melanoma
lines were stained with mouse IgG1κ, the same antibody isotype as DR4 and DR5,
under the same conditions. After incubation, cells were washed twice with staining
buffer and resuspended in 500 µl of staining buffer and analyzed on BD FACS
Canto II using Diva software (BD Bioscience, San Jose, CA).
D. Apoptosis Assay. Cells were trypsinized, harvested, washed twice with cold PBS
and resuspended in 100 μl of Annexin-V binding buffer at a concentration of 1x103
cells/μl. According to manufacturer’s protocol, cells were incubated with 5 μl of
FITC-Annexin-V and propidium iodide (PI) for 15 minutes at room temperature in
the dark (FITC-Annexin-V Kit Apoptosis Detection Kit I, BD Pharminogen).
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Stained cells were analyzed on BD FACS Canto II using Diva software. Single
color controls (Annexin-V or PI only) were used to set up compensation and
quadrants for FACS.
E. Western Blot Analysis. Total cell lysates were prepared using RIPA lysis buffer
(Sigma) containing 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and 50 mM Tris, pH 8.0 plus a
1x cocktail of protease inhibitors (Protease Inhibitor Cocktail Set I, Calbiochem).
Cells were lysed for 30 minutes at 4°C followed by centrifugation for 10 minutes
at 10,000 rpm at 4°C. Protein concentrations were determined using BCA protein
assay (Pierce). A 35 μg protein aliquot was mixed with 4x Laemmli’s SDS sample
buffer (0.02% Bromophenol Blue (BPB), 8% Beta-mercaptoethanol (BME), 8%
SDS, 40% glycerol and 250 mM Tris-HCl, pH 6.8). Cell lysates were heated for
five minutes at 100°C, resolved by 12% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. The
membrane was blocked with 5% non-fat milk or 5% BSA for ≥1 hour and incubated
with primary antibodies for PARP and caspase 8 (Cell Signaling). After incubation,
the membrane was incubated with secondary anti-rabbit or mouse horseradish
peroxidase (HRP)-conjugated antibodies (Biorad).

Proteins were visualized

through development by enhanced chemiluminescence (ECL 2 Western Blotting
Substrate, Pierce) and exposure on X-ray film. The blots were reprobed for β-actin
to confirm equal protein loading.
F. Statistical Analysis. Student t-test was used to determined significance. P values
less than 0.05 were deemed significant.
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3.4 Results.
Melanoma Death Receptor Expression. To test rhTRAIL-sensitivity, malignant
melanoma lines were treated with and without 100 ng/ml of rhTRAIL for 72 hours. Prior
to treatment, control experiments were done to determine the optimal conditions for
rhTRAIL-treatment (data not shown). The treatment of 100 ng/ml for 72 hours was
selected to best distinguish between rhTRAIL-sensitive and rhTRAIL-resistant
melanomas. Post-treatment cells were analyzed for induction of apoptosis through FITCAnnexin-V and PI staining followed by FACS analysis (Fig. 2A&B). Two of the four
lines, A375 and WM9, underwent apoptosis in response to rhTRAIL-treatment, whereas,
the other two, MeWo and WM164, did not. In response to rhTRAIL-treatment, A375
formed 29.2±2.0% apoptotic cells (P<0.001) and WM9 formed 36.9±0.5% apoptotic cells
(P<0.001), however, MeWo and WM164 did not form significant apoptotic cells as
compared to the control (P>0.05). To confirm the event of rhTRAIL-induced apoptosis,
western blotting was employed using antibodies to various components of the apoptotic
cascade. rhTRAIL significantly induced apoptosis in A375 and WM9 noted by the
fragmentation of the DNA repair enzyme Poly-(ADP) Ribose Polymerase (PARP) but this
did not occur in rhTRAIL-resistant melanomas, MeWo and WM164 (Fig. 2C). Treatment
with rhTRAIL was able to effectively initiate the extrinsic pathway of apoptosis in
rhTRAIL-sensitive lines, A375 and WM9, as indicated by the cleavage of procaspase 8 to
caspase 8 which was not present in rhTRAIL-resistant lines, MeWo and WM164, postrhTRAIL-treatment (Fig. 2C).
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Figure 3.1. Death Receptor Membrane Expression. Membrane expression of
rhTRAIL-binding receptors DR4 and DR5 on metastatic malignant melanomas. A)
Membrane expression of DR4. Mean Fluorescent Intensity (MFI) ± SEM (n=9). B)
Membrane expression of DR5. MFI ± SEM (n=9). D) Melanoma DR expression
normalized to non-cancerous melanocytes.
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Melanoma rhTRAIL-Sensitivity.

To test rhTRAIL-sensitivity, metastatic

malignant melanoma lines were treated with and without 100 ng/ml of rhTRAIL for 72
hours. Post-treatment cells were analyzed for induction of apoptosis through FITCAnnexin-V and PI staining followed by FACS analysis (Fig. 2A&B). Two of the four
lines, A375 and WM9, underwent apoptosis in response to rhTRAIL-treatment, whereas,
the other two, MeWo and WM164, did not. In response to rhTRAIL-treatment, A375
formed 29.2±2.0% apoptotic cells (P<0.001) and WM9 formed 36.9±0.5% apoptotic cells
(P<0.001), however, MeWo and WM164 did not form significant apoptotic cells as
compared to the control (P>0.05). To confirm the event of rhTRAIL-induced apoptosis,
western blotting was employed using antibodies to various components of the apoptotic
cascade. rhTRAIL significantly induced apoptosis in A375 and WM9 noted by the
fragmentation of the DNA repair enzyme Poly-(ADP) Ribose Polymerase (PARP) but did
not occur in rhTRAIL-resistant melanomas, MeWo and WM164 (Fig. 2C). Treatment with
rhTRAIL was able to effectively initiate the extrinsic pathway of apoptosis in rhTRAILsensitive lines, A375 and WM9, as indicated by the cleavage of procaspase 8 to caspase 8
which was not present in rhTRAIL-resistant lines, MeWo and WM164, post-rhTRAILtreatment (Fig. 2C).
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Figure 3.2. rhTRAIL-sensitivity. A) Percent apoptotic cells ± SEM. Average of three
independent assays (n=9). B) Representative histogram. Lower left quadrant: Viable
cells (Annexin-/PI-), Lower right quadrant: Early apoptotic cells (Annexin+/PI-), Upper
right quadrant: Late apoptotic cells (Annexin+/PI+). C) Melanoma lines ± rhTRAIL
subjected to western blot analysis and probed with anti-PARP or anti-caspase 8. β-actin
was used as a loading control for each membrane. Representative β-actin is depicted.
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3.5 Discussion.
rhTRAIL holds great promise as an anti-cancer therapeutic. However, there are
still challenges for selecting patients that will benefit from rhTRAIL-based treatments as
the use of rhTRAIL is only advantageous to patients with rhTRAIL-sensitive tumors. It is
instrumental to develop a sensitive and rapid test to identify patients who are well-suited
for rhTRAIL-based therapy.

Here we propose a flow cytometry-based companion

diagnostic assay to measure the membrane expression of DRs on tumors cells isolated from
cancer patients. By first determining DR membrane expression, rhTRAIL can be more
appropriately applied to patients with tumors pre-disposed to the effects of rhTRAIL.
rhTRAIL clinical trials held with patients pre-screened for DR expression will allow for
the more successful clinical application of rhTRAIL. Using an advanced metastatic
malignant melanoma model, the potential utilization of DR4 and DR5 as markers for
rhTRAIL-sensitivity was tested.

Heterogeneity in rhTRAIL-sensitivity was seen in the panel of four malignant
melanoma lines analyzed. In response to rhTRAIL-treatment, two out of the four lines
were sensitive to rhTRAIL-induced apoptosis and two were resistant. In rhTRAILsensitive lines, A375 and WM9, the hallmark events of apoptosis, generation of apoptotic
cells (Annexin-V+ cells) (18) and the fragmentation of the DNA repair enzyme PARP (19),
occurred. However, these events did not transpire in rhTRAIL-resistant lines, MeWo and
WM164, in response to rhTRAIL-treatment.

The mechanism of rhTRAIL-induced

apoptosis is mediated through the activation of the extrinsic pathway of apoptosis. The
extrinsic apoptotic pathway is initiated by the binding of rhTRAIL to DR4 and/or DR5
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followed by the subsequent activation of initiator caspase, caspase 8, from its pro-form
procaspase 8. Caspase 8 can then cleave and activate downstream executioner caspases
which ultimately carry out the events of apoptosis (7,20). Here we show that rhTRAIL is
able to efficiently activate the extrinsic pathway of apoptosis in rhTRAIL-sensitive
melanoma lines but not in rhTRAIL-resistant lines. This is evidenced by the formation of
caspase 8 in rhTRAIL-sensitive lines, A375 and WM9, but not in rhTRAIL-resistant lines,
MeWo and WM164, in response to rhTRAIL-treatment. The use of metastatic malignant
melanomas for the analysis of potential markers for rhTRAIL-based treatments is pertinent
due to the varying sensitivity among malignant melanomas to rhTRAIL (21,22). This
variability represents the broad range of rhTRAIL-sensitivities seen in the patient
population (23). Through tumor profiling, patients can be matched with treatments that
are more likely to be effective with fewer side effects. Highlighting the need to develop
an in vitro clinical test to select patients that will benefit from rhTRAIL-treatment.

Decades of research have uncovered numerous mechanisms cancer cells use to
evade rhTRAIL-induced apoptosis. One mechanism of rhTRAIL-resistance is mediated
by the upregulation of anti-apoptotic proteins termed inhibitors of apoptosis proteins
(IAPs), specifically cFLIP, XIAP, cIAP and survivin, which inhibit caspase activity and
prevent cell death (24–26). Likewise, the equilibrium between pro- and anti-apoptotic
members of the Bcl-2 family play an important role in regulating rhTRAIL-sensitivity.
Overexpression of anti-apoptotic proteins, Bcl-2 and Bcl-xL, correlate highly with
rhTRAIL-resistance. While, downregulation of pro-apoptotic Bcl-2 proteins, Bax and Bak,
render cells resistant to rhTRAIL (27–29).
70

Lastly, the optimum expression of pro-

apoptotic rhTRAIL-receptors is indispensable in promoting apoptosis. rhTRAIL binds to
five receptors: two pro-apoptotic and three anti-apoptotic. Pro-apoptotic receptors, DR4
and DR5, contain cytoplasmic death domains through which rhTRAIL can initiate
apoptosis. Anti-apoptotic receptors, decoy receptor 1 (DcR1), decoy receptor 2 (DcR2)
and osteoprotegerin (OPG), act as antagonistic receptors.

These receptors lack an

intracellular death domain and cannot transmit an apoptotic signal upon rhTRAIL-binding
(30).

Finding a predictive marker for rhTRAIL-sensitivity is challenging due to the
extreme complexity of rhTRAIL-resistance. However, the membrane expression of DRs
holds the most promise. Since DRs are at the most apical part of the rhTRAIL-induced
apoptotic pathway without adequate levels of membrane-bound DRs there can be no
induction of apoptosis regardless of other anti-apoptotic factors. Originally, the differential
expression of pro- verses anti-apoptotic receptors was thought to be the cause for the
difference in rhTRAIL-sensitivity. However, studies have shown that the distribution
between pro- and anti-apoptotic receptors does not correlate with sensitivity (9). Several
studies have demonstrated that downregulation of pro-apoptotic receptors DR4 and DR5
on the membrane of cancer cells is instrumental in conveying rhTRAIL-resistance
(21,31,32). Data shows that lack of DR membrane expression correlates with rhTRAILresistance regardless of alterations in the levels of IAPs or anti-apoptotic Bcl-2 proteins.
Additionally, although mRNA for DR4 and DR5 is present in the vast majority of cancer
cells, due to post-translational modifications and intracellular trafficking, total receptor
expression does not reflect the functional membrane expression of DR4 and DR5 (13,33).
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Therefore, the best reflection of rhTRAIL-sensitivity is the amount of DRs on the cancer
cell membrane. Additionally, the marker for rhTRAIL-sensitivity needs to be applicable
to a rapid and high-throughput clinical test. For measuring DR4 and DR5, there are already
sensitive and specific fluorescent antibodies commercially available.

Finally, the

utilization of a flow cytometry-based technique allows for the rapid interrogation of
isolated tumor cells with little sample preparation that can be easily integrated into clinical
testing.

Preliminary results show a direct correlation between DR expression and sensitivity
to rhTRAIL-induced apoptosis.

rhTRAIL-resistant lines, MeWo and WM164, had

significantly less DR4 and DR5 expressed on their membrane expression compared to the
rhTRAIL-sensitive lines, A375 and WM9. On average the rhTRAIL-sensitive melanoma
lines had nearly four-fold more DR4 membrane expression. For DR5, on average the
rhTRAIL-sensitive melanoma lines had over two-fold more membrane expression than
rhTRAIL-resistant lines.

Here we provide preliminary data for the association between DR membrane
expression and rhTRAIL-sensitivity. rhTRAIL-sensitive cancers have significantly higher
membrane expression of both DR4 and DR5 than rhTRAIL-resistant cancers. Yet, even
resistant cancers still express some levels of DR4 and DR5; although, they do not undergo
apoptosis in response to rhTRAIL-treatment. We have shown that the non-transformed
counterpart of melanomas, melanocytes, are resistant to rhTRAIL-induced apoptosis even
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though they do expressed DR4 and DR5 on their cell membrane. However, normal
melanocytes have a much lower membrane expression of both DR4 and DR5 as compared
to rhTRAIL-sensitive melanoma cells (6).

For a cell to undergo rhTRAIL-induced

apoptosis a threshold for apoptosis activation must be surpassed. In order for a cell to
activate the process of apoptosis a certain amount of caspase 8 must be activated through
the binding of DR4 and/or DR5 by rhTRAIL (34). Conclusively, cancer cells must express
an optimum amount of DRs on the cell membrane to overcome the apoptotic threshold and
render them sensitive to rhTRAIL. Our data suggests that a two-fold increase in DR
expression compared to normal cells is enough to render cancer cells sensitive to rhTRAILinduced apoptosis.

More research is needed to confirm the threshold between DR

membrane expression and rhTRAIL-sensitivity. Utilizing both established cancer cell
lines and patient samples, a clinical reference range of DR expression must be set to
determine a patient’s suitability for rhTRAIL-treatment and for the successful execution of
this companion diagnostic test.

Utilizing a flow cytometry-based technique, we show the value of measuring DR
membrane expression to predict rhTRAIL-sensitivity on established malignant melanoma
cell lines. This technique can be easily translated into a clinical test to characterize tumor
cells isolated from patients, applicable to both solid and hematological cancers. The use
of flow cytometry to analyze solid tumors is relatively novel and includes samples from
surgical specimens, fine needle aspirations or frozen or paraffin-embedded tissues.
Analysis of solid tissue involves the disaggregation of the sample into a single cell
suspension. This can be accomplished either mechanically or with enzymes such as
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collengase or a combination of both (35–37). Flow cytometry in the analysis and diagnosis
of hematological cancers such as leukemia and lymphoma is well established and is
currently clinically utilized (38,39). The application of multiparameter flow cytometry
allows for the rapid and sensitive detection of abnormal cells in a tumor sample or whole
blood. Abnormal cells are identified by the presence of antigens such as clusters of
differentiation (CD) that differs significantly from their normal counterpart (40).
Therefore, DR4 and DR5 can be easily added to the panel of markers used to diagnosis
these cancers. However, the clinical development of measuring DRs to predict rhTRAILsensitivity requires the optimization of blood volume and tissue collected to ensure an
adequate number of cells is obtained.

The pre-clinical and early clinical trials of rhTRAIL demonstrated promising
results. rhTRAIL acted as a potent pro-apoptotic molecule and could be systemically
applied without any major adverse effects. However, once rhTRAIL proceeded further
into clinical trials, alone and in combination with traditional therapies, the results were
disappointing. Clinical trials were performed without prescreening patients’ tumors for
DR membrane expression and the unselected treatment of patients with rhTRAIL resulted
in a lack of clinical benefit. These data provide the rationale to implement a flow
cytometry-based technique to profile tumor cells isolated from patients for DR membrane
expression in order to determine their suitability for rhTRAIL-treatment. If patients can
be screened for DR expression, they can be more appropriately selected for rhTRAIL
clinical trials and give rhTRAIL a fighting chance to act as an effective anti-cancer therapy
by giving it to patients that are well-suited for it.
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CHAPTER IV
SENSITIZATION OF RHTRAIL-RESISTANT MALIGNANT MELANOMAS BY
QUERCETIN

4.1 Abstract.
Malignant melanoma is the most commonly-diagnosed skin cancer associated with
a high rate of metastasis. Early stage melanoma is easily treated, but metastatic malignant
melanoma is one of the most treatment-refractory malignancies with low survival rates.
The application of recombinant human Tumor Necrosis Factor-Related ApoptosisInducing Ligand (rhTRAIL) for the treatment of metastatic malignant melanoma holds
considerable promise due to its selective pro-apoptotic activity towards cancer cells and
not non-transformed cells. Unfortunately, the clinical utilization of rhTRAIL has been
terminated due to the resistance of many cancer cells to undergo apoptosis in response to
rhTRAIL. However, rhTRAIL-resistance can be abrogated through the co-treatment with
compounds derived from “Mother Nature” such as quercetin that can modulate cellular
components responsible for rhTRAIL-resistance. Here we show that rhTRAIL-resistant
malignant melanomas can be sensitized by quercetin mediated by the upregulation of
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rhTRAIL-binding receptors DR4 and DR5 and the proteasome-mediated downregulation
of the anti-apoptotic protein FLIP.

4.2 Introduction.
The frequency of malignant melanoma has been on the rise over the last 30 years.
Although it is the least diagnosed of the skin cancers, it is associated with the highest rate
of mortality. When the melanoma is localized to the epidermis, the survival rate is 98%.
However, once the cancer metastasizes the 5-year survival rate decreases to 17% (1). The
decrease in survival rate correlates with the lack of effective treatment options for
metastatic malignant melanoma. Current therapies (chemotherapy, radiation therapy,
targeted therapy and immunotherapy) are characterized by slow effectiveness and only
transient anti-tumor properties due to acquired resistance. In addition, a high degree of
negative side effects are associated with these therapies which deeply impacts the patient’s
quality of life and limits the optimum drug dose. As a result, there is no standard
therapeutic regimen for metastatic malignant melanoma (2,3). It is vital to invest in the
development of novel therapeutics for metastatic malignant melanoma and increase the
survival outcome for these patients.

The application of recombinant human Tumor Necrosis Factor-Related ApoptosisInducing Ligand (rhTRAIL) as a treatment for human cancer holds great promise due to
its ability to selectively induce apoptosis in cancer cells while not harming normal nontransformed cells (4,5). rhTRAIL, the optimized form of the cytokine TRAIL, consists of
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only the biologically active C-domain of endogenous molecule. rhTRAIL selectively
induces apoptosis by interacting with membrane-bound extracellular receptors, death
receptor (DR) 4 and DR5, which are more abundantly expressed on cancer cells compared
to normal cells (6). Upon rhTRAIL-binding, the extrinsic pathway of apoptosis is initiated
characterized by the activation of caspase 8 followed by the activation of executioner
caspases 3, 6 and 7. Additionally, mediated by the caspase 8 cleavage of BID to tBID,
rhTRAIL can indirectly activate the intrinsic pathway of apoptosis independently of p53.
Once activated, tBID will translocate to the mitochondria and stimulate the release of
cytochrome c into the cytosol and ultimately resulting in the activation of caspase 9.
Caspase 9 can then cleave and activate executioner caspases which carry out the hallmark
events of apoptosis including DNA fragmentation and cytoplasmic condensation (7).

Although the application of rhTRAIL as an anti-cancer therapeutic holds great
promise, the clinical use has been limited due to the heterogeneity seen in rhTRAILsensitivity among cancers. This is especially prevalent in cases of advanced metastatic
malignant melanoma. Nearly two-thirds of melanoma cells are resistant to rhTRAILinduced apoptosis, including melanomas directly isolated from cancer patients (8,9).
Melanoma rhTRAIL-resistance can be attributed to a number of different causations.
Specifically, the decreased membrane expression of pro-apoptotic rhTRAIL-binding
receptors DR4 and DR5 (10,11)(site DR paper). The lack of receptor expression may be
associated with gene mutations or decreased transcription (12,13). Additionally, failure to
transport the receptors to the membrane or constitutive endocytosis can lead to the
decreased expression of DRs on cancer cells (14–16). Moreover, the upregulation of
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intracellular anti-apoptotic proteins plays an indispensable role in rhTRAIL-resistance.
The equilibrium between pro- and anti-apoptotic members of the Bcl-2 family takes part
in regulating rhTRAIL-sensitivity. Overexpression of anti-apoptotic proteins, Bcl-2 and
Bcl-xL, correlates highly with rhTRAIL-resistance.

While, inactivation of the pro-

apoptotic Bcl-2 proteins, Bax and Bak, along with the Bcl-xL-mediated sequestering of
tBID, renders cells resistant to rhTRAIL (17–19). Another mechanism of rhTRAILresistance is mediated through the increased expression of inhibitors of apoptosis proteins
(IAPs) such as FLIP, XIAP, cIAP and survivin that inhibit caspase activity (12,20). It is
essential to understand the molecular mechanism of rhTRAIL-resistance and develop ways
to overcome this resistance through combination therapy.

Epidemiological evidence shows that a plant-based diet is associated with a
decrease incidence of various types of cancers. The benefit of which is most accredited to
the natural phytochemicals such as flavonoids present.

One of the most prevalent

flavonoids with potent physiological activity is quercetin. Quercetin is found in a wide
variety of sources ranging from onions and apples to red wine (9). As a pleiotropic
molecule, quercetin exhibits its anti-cancer effects on a number of different pathways such
as cell survival pathways, cell cycle arrest, upregulation of tumor suppressor genes,
downregulation of anti-apoptotic proteins and pro-apoptotic pathways (21–26). Most
noteworthy is the impact quercetin has on the expression of DR5. Several studies show
that quercetin can upregulate DR5 on the membrane of cancer cells through enhanced
transcription (27–31). Moreover, it has been demonstrated that quercetin is able to
downregulate a number of anti-apoptotic proteins that promote rhTRAIL-resistance,
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specifically FLIP, Mcl-1 and survivin (26,32). Overall, this evidence shows the potential
of quercetin as a co-treatment for rhTRAIL. The ability of quercetin to sensitize rhTRAILresistant malignant melanomas has yet to be evaluated. Here we test the combination
rhTRAIL plus quercetin to overcome the intrinsic resistance of metastatic malignant
melanomas to rhTRAIL.

4.3 Methods.
A. Drugs and Chemicals. Recombinant human Tumor Necrosis Factor-Related
Apoptosis-Inducing Ligand (rhTRAIL) was produced according to well defined
and previously detailed protocols (6). Quercetin dihydrate (Calbiochem) was
dissolved in Polyethylene Glycol (PEG)-400 (Fisher Scientific).

MG132

(Calbiochem) was dissolved in dimethyl sulfoxide (DMSO).
B. Cell Culture. WM164 cells were maintained in DMEM and MeWo cells were
maintained in RPMI, both supplemented with 10% Fetal Bovine Serum (FBS) and
1% Antibiotic/Antimycotic Solution. Cells were incubated in a 90% humidified
atmosphere with 5% CO2 at 37⁰C.
C. Apoptosis Assay. Cells were trypsinized, harvested, washed twice with cold PBS
and resuspended in 100 μl of Annexin-V binding buffer at a concentration of 1x103
cells/μl. According to manufacturer’s protocol, cells were incubated with 5 μl of
FITC-Annexin-V and Propidium Iodide (PI) for 15 minutes at room temperature in
the dark (FITC-Annexin-V Kit Apoptosis Detection Kit I, BD Pharminogen).
Stained cells were analyzed on BD FACS Canto II using Diva software. Single
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color controls (Annexin-V or PI only) were used to set up compensation and
quadrants for FACS.
D. Western Blot Analysis. Total cell lysates were prepared using RIPA lysis buffer
(Sigma) containing 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and 50 mM Tris, pH 8.0 plus a
1x cocktail of protease inhibitors (Protease Inhibitor Cocktail Set I, Calbiochem).
Cells were lysed for 30 minutes at 4°C followed by centrifugation for 10 minutes
at 10,000 rpm at 4°C. Protein concentrations were determined using BCA protein
assay (Pierce). A 35 μg protein aliquot was mixed with 4x Laemmli’s SDS sample
buffer (0.02% Bromophenol Blue (BPB), 8% Beta-mercaptoethanol (BME), 8%
SDS, 40% glycerol and 250 mM Tris-HCl, pH 6.8). Cell lysates were heated for
five minutes at 100°C, resolved by 12% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. The
membrane was blocked with 5% non-fat milk or 5% BSA for ≥1 hour and incubated
with primary antibodies for PARP, caspase 8, caspase 3, Bid, caspase 9, caspase 6,
caspase 7, FLIP, DR4 and DR5 (Cell Signaling). After incubation, the membrane
was incubated with secondary anti-rabbit or mouse horseradish peroxidase (HRP)conjugated antibodies (Biorad). Proteins were visualized through development by
enhanced chemiluminescence (ECL 2 Western Blotting Substrate, Pierce) and
exposure on X-ray film. The blots were reprobed for β-actin to confirm equal
protein loading.
E. Cytochrome c Release. Cells were resuspended in permeabilization buffer (400
µg/mL digitonin, 75 mM KCl, 1mM NaH2PO4, 8 mM Na2HPO4 and 250 mM
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sucrose) plus protease inhibitors. Samples were incubated for 10 minutes at 4°C,
centrifuged at 16,000 g for five minutes at 4°C and the supernatants were kept as
the cytosolic fraction. Samples were quantified as described above and 60 μg was
resolved on a 15% gel. As described above, the gel was transferred to PVDF,
blocked and incubated with anti-cytochrome c (Cell Signaling) and visualized by
chemiluminescence.
F. Death Receptor Membrane Expression. Cells were collected with enzyme-free
PBS-based cell dissociation buffer (Gibco Life Technologies) and stained with
mouse anti-human DR4 and DR5 conjugated to phycoerythrin (PE) (eBioscience).
Briefly, 0.25x106 cells were incubated in 100 µl of staining buffer (2% FBS, 0.02%
sodium azide in PBS) and 5 µl anti-DR4 or anti-DR5 for one hour on ice in the
dark. As a negative control, cells were stained with mouse IgG1κ isotype antibody
under the same conditions. After incubation, cells were washed twice with staining
buffer and resuspended in 500 µl of staining buffer and analyzed on BD FACS
Canto II using FACS Diva software. For the permeabilization experiments, after
the first antibody incubation cells were fixed in 4% paraformaldehyde for 10
minutes at room temperature and permeabilized with 0.1% saponin for 5 minutes
at room temperature. Cells were then incubated with anti-IgG1κ, DR4 or DR5 for
30 minutes in the saponin buffer and analyzed by FACS.

To calculate the

cytoplasmic DR expression, the permeablized cells representing the total DR
expression was subtracted from the unpermeablized cells representing membranebound DRs.
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G. Reverse Transcription-PCR. Total RNA was extracted using TRIzol reagent
(Ambion) and treated with DNase according to manufacturer’s protocol (Invitrogen
Deoxyribonuclease I, Amplification Grade). RT-PCR was performed following the
manufacturer’s protocol (Invitrogen SuperScript III One-Step RT-PCR System
with Platinum® Taq DNA Polymerase). Human DR5 mRNA was amplified using
the forward primer 5’-GGGAGCCGCT-CATGAGGAAGTTGG-3’ and the
reverse primer 5’-GGCAAGTCTCTCTCCCAGCGTCTC-3’. For DR4, forward
primer

5’-GAGCAACGCAGACTCGCT-3’and

TCACTCCAAGGACACGGC-3’ were used.
CTTGGCCAATTTGCCTGTAT-3’and

the

reverse

primer

5’-

For FLIP, forward primer 5’-

the

reverse

primer

5’-

CCCATGAACATCCTCCTGAT-3’ were used. For β-actin, the forward primer
5’-TGACGGGGTCACCCACACTGTGCC-3’and

the

CTGCATCCTGTCGGCAATGCCAG-3’ were used.

reverse

primer

5’-

cDNA synthesis was

performed at 60ºC for 30 minutes using the Applied Biosystems GeneAmp PCR
System 9700. The PCR cycling conditions (30 cycles) were as follows: denature
for 2 minutes at 94ºC, anneal for 30 seconds at 55ºC for FLIP and DR4 and 65ºC
for DR5 and β-actin, extend for 1 minute and 30 seconds at 68ºC, and execute a
final extension for 10 minutes at 68ºC. Reaction products were analyzed on 1.2%
agarose gels. The bands were visualized by ethidium bromide and an UV.
H. Statistical Analysis. Student t-test was used to determined significance. P values
less than 0.05 were deemed significant.
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4.4 Results.
rhTRAIL sensitivity.

Metastatic malignant melanoma cell lines MeWo and

WM164 were tested for their sensitivity to rhTRAIL-induced apoptosis in vitro. Cells were
treated with increasing concentrations of rhTRAIL ranging from 5 ng/ml to 1 µg/ml for 72
hours. Levels of rhTRAIL-induced apoptosis were determined by FITC-Annexin-V and
PI staining followed by FACS analysis (Fig. 1 A-C).

Both melanoma lines were

completely resistant to rhTRAIL-induced apoptosis. Treatment with rhTRAIL, even at the
highest tested treatment concentration of 1 µg/ml, did not result in the formation of
apoptotic cells as indicated by the lack of Annexin-V+ and/or Annexin-V+ and PI+ cells
as compared to the control (P>0.05). The rhTRAIL-resistant status of the melanoma lines
were confirmed by western blotting utilizing antibodies to various components of the
apoptotic cascade (Fig. 1 D&E). Both lines were completely resistant to rhTRAIL-induced
apoptosis and did not show any Poly (ADP-ribose) polymerase (PARP) cleavage or
activation of any proteins in the apoptotic pathway.
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Figure 4.1. rhTRAIL sensitivity. Sensitivity of malignant melanomas MeWo and
WM164 to rhTRAIL in vitro. A) Average of three independent assays ± SEM. B)
Representative histogram of MeWo. C) Representative histogram of WM164. Lower
left quadrant: Viable cells (Annexin-/PI-), Lower right quadrant: Early apoptotic cells
(Annexin+/PI-), Upper right quadrant: Late apoptotic cells (Annexin+/PI+). D) MeWo and
B) WM164 ± rhTRAIL subjected to western blot analysis and probed with anti-PARP,
caspase 8, Bid, cytochrome c, caspase 9, caspase 3, caspase 6 and caspase 7. β-actin was
used as a loading control for each membrane. Representative β-actin is depicted.
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rhTRAIL plus quercetin apoptosis. To overcome the intrinsic rhTRAIL-resistance
of MeWo and WM164, the combination treatment of rhTRAIL plus quercetin was
employed.

Melanoma lines were treated with single agent rhTRAIL at 250 ng/ml,

quercetin at 25 and 50 µM and with the combination of the single agents. Post treatment
cells were collected and analyzed for induction of apoptosis through Annexin-V and PI
staining and western blotting probing for key proteins in the apoptotic pathways (Fig. 2).
Alone, quercetin induced minimal levels of apoptosis in the rhTRAIL-resistant melanoma
cells. For MeWo there was no significant induction of apoptosis when treating with both
concentrations of quercetin marked by the lack of Annexin-V+ and/or Annexin-V+ and
PI+ cells as compared to the control (P>0.05) (Fig. 2 A&B). The lack of quercetin-induced
apoptosis was confirmed by western blot where there was no PARP cleavage or activation
of any pro-apoptotic proteins (Fig. 2D). However, in WM164, quercetin was able to induce
minimal levels of apoptosis with the formation of 10.5±0.7% apoptotic cells at 25 µM and
19.1±1.6% apoptotic cells at 50 µM (P<0.05) (Fig. 2 A&C). Probing for apoptotic proteins
did not reveal any PARP cleavage or protein activation the in quercetin-treated WM164
cells as the low levels of apoptosis was not sufficient to be detected by western blotting
(Fig. 2E). Furthermore, by combining rhTRAIL plus quercetin the minimal levels of
apoptosis induced in the single agent treatments were dramatically increased in both
melanoma lines. This was evidenced by the significantly higher formation of Annexin-V+
and/or Annexin-V+ and PI+ cells as compared to any single agent treatments (P<0.05)
(Fig. 2 A-C). The augmentation of apoptosis occurred dose-dependently in respect to
quercetin. The ability of quercetin to sensitize rhTRAIL-resistant melanomas to undergo
apoptosis was confirmed by western blotting (Fig. 2 D&E). In both melanoma lines, PARP
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was cleaved in only the co-treatment group dose-dependently. By adding quercetin to the
rhTRAIL-treatment, the once resistant cells were sensitized to activate the rhTRAILmediated extrinsic pathway of apoptosis as marked by the cleavage of pro-caspase 8 to
caspase 8. Additionally, through the co-treatment the intrinsic pathway of apoptosis was
activated in WM164 but not in MeWo as noted by the cleavage of BID to tBID followed
by the release of cytochrome c into the cytosol and the activation of caspase 9 from procaspase 9. Finally, through the co-treatment executioner caspases were activated. In both
melanoma lines caspase 3 was activated through the co-treatment, caspase 6 in only the
highest co-treatment in WM164 and caspase 7 in the highest co-treatment in both
melanoma lines.
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Figure 4.2. rhTRAIL plus quercetin apoptosis. Combination treatment-induced
apoptosis. A) Average of three independent assays ± SEM. B) Representative histogram
of MeWo. C) Representative histogram of WM164. Lower left quadrant: Viable cells
(Annexin-/PI-), Lower right quadrant: Early apoptotic cells (Annexin+/PI-), Upper right
quadrant: Late apoptotic cells (Annexin+/PI+). D) MeWo and B) WM164 ± rhTRAIL
subjected to western blot analysis and probed with anti-PARP, caspase 8, Bid,
cytochrome c, caspase 9, caspase 3, caspase 6 and caspase 7. β-actin was used as a
loading control for each membrane. Representative β-actin is depicted.
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Quercetin regulation of death receptors. The addition of quercetin to rhTRAIL
was able to promote the activation of the rhTRAIL-mediated extrinsic apoptotic pathway
evidenced by the activation of caspase 8 in only the co-treatment groups. To elucidate the
mechanism of quercetin sensitization, the most apical part of the extrinsic apoptotic
pathway, expression of rhTRAIL-binding receptors DR4 and DR5 were examined in
response to quercetin-treatment (Fig. 3). Quercetin was able to upregulate the membrane
expression of DR4 in both melanoma lines dose-dependently (Fig. 3A). In response to
quercetin-treatment, MeWo upregulated DR4 on the cell membrane over four-fold at 25
µM and over 11-fold at 50 µM (P<0.001). For WM164, DR4 was upregulated nearly fivefold and seven-fold at 25 µM and 50 µM, respectively (P<0.001). For DR5, the membrane
expression was only upregulated in melanoma line WM164 dose-dependently with a
quarter-fold increase at 25 µM and a half-fold increase at 50 µM (P<0.001) (Fig. 3B).
However, this did not occur in MeWo cells (P>0.05). To further examine the effects of
quercetin on the regulation of DR4 and DR5 the total protein expression and mRNA levels
were analyzed post-treatment with quercetin (Fig. 3 C-E). For DR4 there was no change
in the total protein expression or the mRNA message in both melanoma lines. For DR5,
there was no change in the total protein expression or the mRNA in MeWo. However,
there was a dose-dependent upregulation of the total DR5 protein and DR5 mRNA in
WM164. To explain the increase in the membrane expression of DR4 but the lack of
increase in total protein and mRNA in response to quercetin-treatment, the non-membrane
levels of DR4 was measured (Fig. 3 F&G). In both melanoma lines there was significant
levels of DR4 within the cell. However, with the application of quercetin the nonmembrane levels of DR4 decreased while the membrane levels increased (P<0.001).
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Figure 4.3. Quercetin regulation of death receptors. Effects of quercetin on DR4 and
DR5 expression. A) Membrane expression of DR4. Mean Fluorescent Intensity (MFI) ±
SEM. B) Membrane expression of DR5. MFI ± SEM. C) Total DR4 protein. D) Total
DR5 protein. E) DR4 and DR5 mRNA signal. F) Membrane versus non-membrane DR4
expression in MeWo. G) Membrane versus non-membrane DR4 expression in WM164.
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Quercetin regulation of FLIP. Also a player in the most apical part of the extrinsic
apoptotic pathway, FLIP expression is a major regulatory point for rhTRAIL-sensitivity.
Here we wished to see the potential regulation of FLIP by quercetin. Quercetin was able
to dose-dependently downregulate the protein expression of FLIP in both melanoma lines
(Fig. 4A). To see if quercetin transcriptional downregulates FLIP, the mRNA signal of
FLIP in response to quercetin-treatment was measured (Fig. 4B). Here we found no change
in the transcript signal in both lines. Another mechanism of protein downregulation is
mediated through proteasomal degradation.

To test if quercetin promotes the

downregulation of FLIP mediated through the proteasome, the proteasome inhibitor
MG132 was employed (Fig. 4C). By co-treating quercetin and MG123 we were able to
prevent the downregulation of FLIP and show that quercetin downregulates FLIP by
promoting proteasome degradation.

98

Figure 4.4. Quercetin regulation of FLIP. Effects of quercetin on FLIP expression.
A) Total FLIP protein. B) FLIP mRNA signal. C) Quercetin plus proteasome inhibitor
MG132 on total FLIP protein.
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4.5 Discussion.
The selectively of rhTRAIL to induce robust levels of apoptosis in cancer cells
makes it a prime candidate for the treatment of metastatic malignant melanoma.
Unfortunately, the once promised molecule has been suspended due to the resistance
exhibited by various cancers to undergo apoptosis in response to rhTRAIL. Understanding
the molecular mechanisms of rhTRAIL-resistance is essential to formulating a combination
therapy to sensitize resistant malignant melanomas. Here we evaluate the plant-derived
flavonoid quercetin as a potential co-treatment for rhTRAIL to overcome melanoma
resistance.

Apoptosis induced by pro-apoptotic receptor agonists such as rhTRAIL is mediated
through the binding of extracellular receptors, DR4 and/or DR5, and the direct activation
of the extrinsic apoptotic pathway along with the indirect activation of intrinsic pathway
(33). Melanoma lines MeWo and WM164, both derived from advanced cases of metastatic
malignant melanoma are among the melanomas resistant to rhTRAIL-induced apoptosis.
Even treating with extremely high concentrations of l μg/ml no event of apoptosis was
marked either lines. The lack of apoptotic Annexin-V+ cells, cleaved PARP or activation
of any key proteins in either the extrinsic or intrinsic pathways evidenced this. However,
the addition of quercetin was able to negate the rhTRAIL-resistance of both MeWo and
WM164. Treating at subcytotoxic concentrations of both single agents, the combination
of rhTRAIL plus quercetin was able to induce apoptosis in both lines apparent by the
significant formation of Annexin-V+ cells, PARP cleavage and activation of executioner
caspases 3, 6 and 7, dose-dependently in respect to quercetin. The combination treatment
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allowed for the activation of the extrinsic apoptotic pathway as noted by the formation of
caspase 8. It is interesting note that in WM164 and not MeWo the intrinsic pathway was
activated through the co-treatment mediated by formation of tBID followed by the release
of cytochrome c from the mitochondria and the activation of caspase 9.

Of the most significance is that the addition of quercetin to rhTRAIL allowed for
the activation of rhTRAIL-mediated extrinsic apoptotic pathway. This is demonstrated by
the cleavage of pro-caspase 8 to caspase 8, a marker for rhTRAIL-induced apoptosis (34).
The activation of caspase 8 in only the co-treatment group implies that quercetin plays a
role in regulating cellular components responsible for controlling rhTRAIL-sensitivity. To
understand the mechanism of the sensitization of rhTRAIL-resistant malignant melanomas
by quercetin, the effects of quercetin on the most apical parts of the extrinsic pathway were
evaluated.

Multiple reports claim that low levels of DRs on the membrane of cancer cells
confers rhTRAIL-resistance (14–16,35).

We have previously shown that rhTRAIL-

resistant melanomas MeWo and WM164 have two-fold less membrane expression of both
DR4 and DR5 compared to rhTRAIL-sensitive melanomas (cite paper). Nonetheless, the
membrane expression of both DR4 and DR5 can be upregulated on melanoma cells via
quercetin. The mechanism in which quercetin executes the upregulation in melanoma cells
differs between DR4 and DR5. DR expression can be transcriptionally regulated or
through post-translation modifications including protein glycosylation, trafficking and
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endocytosis (36).

Here we show that quercetin promotes DR5 upregulation on the

membrane of melanoma WM164 cells as a consequence of quercetin-stimulated gene
transcription. This is illustrated by the correlation between the increased DR5 membrane
expression and an increase in the total DR5 protein and mRNA levels, dose-dependently
in response to quercetin.

Several studies have shown that quercetin is capable of

upregulating DR5 on the membrane of cancer cells mediated through the increased activity
of transcription factors including p53, CHOP and SP1 (28,30,31,36). However, the
transcriptional regulation of DR5 by quercetin has never been evaluated in melanoma cells.
The specific cellular targets responsible for the upregulation of DR5 by quercetin is
unknown and warrants additional study. However, a p53-mediated mechanism can be
excluded because WM164 has an inactivating Y220C mutation in the p53 gene yet
experienced DR5 upregulation (37,38).

Conversely, the robust upregulation of DR4 on the membrane of the melanoma
cells was not by means of enhanced transcription. This is evident by the absence of an
increase in the total protein and mRNA of DR4 in response to quercetin-treatment.
Previous studies have shown that total protein and mRNA levels do not correlate with the
functional membrane expression of DRs. Studies show that some melanoma cells, despite
the presence of mRNA, lack DR4 membrane expression and have high levels of the
receptor within the cytoplasm (13). Additionally, immunohistochemistry staining of DR4
reveals that the receptor can be localized to the trans-Golgi network in melanoma cells
(39). The translocation of DRs from the trans-Golgi network to the plasma membrane is a
complex system regulated by cargo transport proteins such as Arf and ARAP1.
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Malfunctions in this pathway can result in DRs surface deficiency and increased
localization to the cytoplasm (36).

Here we show that both melanoma lines have

substantial levels of DR4 within the non-membrane portion of the cell which substantially
decreases upon quercetin-treatment. We hypothesize that quercetin promotes the vesicular
movement of DR4 from the cytoplasm or the trans-Golgi network to the cellular
membrane. The ability of quercetin to the promote DR4 upregulation on the cancer cell
membrane is a novel finding. The quercetin-mediated upregulation of DR4 has never been
described and warrants thorough examination of the exact mechanism in which quercetin
promotes this movement.

Moreover, the binding of rhTRAIL to DR4 and/or DR5 results in the trimerization
of the receptors leading to the assembly of the intracellular death-inducing signaling
complex (DISC). At the DISC, the adaptor protein, Fas-associated death domain (FADD),
acts as a bridge between the death-receptor complex and the death effector domain (DED)
of the initiator caspase, procaspase 8. Induced proximity results in the autoproteolytic
cleavage of procaspase 8 into its active form, caspase 8. However, the anti-apoptotic
protein FLIP will compete for FADD binding, decreasing the formation of caspase 8 and
impeding the pro-apoptotic signal generated by rhTRAIL-binding. This is a result of the
homology between FLIP and procaspase 8, both possessing a DED yet FLIP lacks caspase
activity (40). The ratio between caspase 8 and FLIP is a major regulator of rhTRAILsensitivity (20,41). Although quercetin has no effect on procaspase 8 levels, we are able
to downregulate FLIP and push the ratio in favor of the pro-apoptotic procaspase 8 and
therefore sensitize the rhTRAIL-resistant melanomas. FLIP levels are maintained by a
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balance between transcription and degradation mediated by the ubiquitin-proteasome
degradation system (42). Here we show that quercetin promotes the downregulation of
FLIP mediated through degradation by the proteasome. This is apparent by the inhibition
of the quercetin-mediated FLIP downregulation when a proteasome inhibitor is applied.
Additional studies have also shown that quercetin is able to downregulate FLIP mediated
by the proteasome however this has never been shown in melanoma (31,43).

Here we provide insight into the molecular mechanisms in which rhTRAIL-induced
apoptosis can be modulated by quercetin in advanced metastatic malignant melanomas.
The application of rhTRAIL is far superior to other therapeutics due the selectivity of
rhTRAIL for only cancer cells while showing no harm to normal healthy cells. This
selectively will result in potent anti-tumor activity with minimal side effects for the patient.
However, the presentation of resistance limits the application of rhTRAIL. Nonetheless,
resistance can be overcome through the co-treatment of rhTRAIL with quercetin and lead
to the sensitization of rhTRAIL-resistant malignant melanomas.
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CHAPTER V
OVERALL CONCLUSION
5.1 Conclusion.

Currently, the incidence of skin cancer is on the rise with the malignant melanoma
subtype being associated with the highest rate of chemo-resistance and death. Upon
metastasis, the five-year survival rate dramatically decreases to 17% from 98% for early
stage malignant melanoma. The lack of a standard therapeutic regimen for advanced
cases malignant melanoma is responsible for the decline in survival rate (1,2). However,
one promising treatment option for malignant melanoma is rhTRAIL.

Herein we show that rhTRAIL possesses potent pro-apoptotic activity in vitro and
in vivo towards malignant melanoma cells. Traditional therapies such as chemotherapy
also induce apoptosis in cancer cells; however, these types of therapeutics are nonspecific. They only induce apoptosis as a result of causing DNA damage or other cellular
stresses and cannot differentiate between cancerous and non-cancerous cells. The lack of
specificity results in severe negative side effects for the patient which limits their quality
of life and prevents the administration of the optimum drug dose (3,4). Conversely,
rhTRAIL is specific for cancer cells only and does not show harm towards normal
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healthy cells. This is apparent by the absence of rhTRAIL-induced apoptosis in the nontransformed counterpart of melanomas, melanocytes. The safety of rhTRAIL is further
confirmed in vivo. The systemic application of rhTRAIL showed no harm to the mice
model with no toxicity to any major organs. The exact mechanism for cancer cellspecific rhTRAIL-induced apoptosis is yet to be elucidated. However, we show that
melanoma cells have a two-fold higher expression of both DR4 and DR5 compared to
melanocytes. The higher expression of DRs may explain why cancer cells are more
sensitive to rhTRAIL compared to normal cells.

Unfortunately, the clinical use of rhTRAIL is limited by the heterogeneity in
sensitivity among cancers. This is especially observed in cases of malignant melanoma.
Many melanomas do not undergo apoptosis in response to rhTRAIL-treatment, even at
extremely high concentrations. Resistance can be due to a multitude of reasons.
However, we find that the optimum expression of DRs on the cancer cell membrane is
essential to overcome the apoptotic threshold and render melanomas sensitive to
rhTRAIL.

Nonetheless, the clinical use of rhTRAIL can get back on the “trail” through
specific measures. Firstly, clinical trials were performed without prescreening patients’
tumors for DR membrane expression. The unselected treatment of patients with
rhTRAIL resulted in a lack of clinical benefit, and the clinical trials failed. However, we
show a correlation between DR membrane expression and rhTRAIL-sensitivity.
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Therefore, the development of an in vitro clinical assay to screen patients’ tumors for DR
expression is essential. If patients are first screened for DR expression, they can be more
appropriately placed in rhTRAIL clinical trials. Moreover, finding combination
treatments for rhTRAIL in order to sensitize resistance melanomas is another method to
overcome the limitations of rhTRAIL. Of special interest are natural compounds derived
from “Mother Nature” that are able modulate some of the cellular components
responsible for rhTRAIL-resistance (5). Here we show the successful co-treatment of
rhTRAIL plus the plant-derived flavonoid quercetin. The resistance of malignant
melanomas to rhTRAIL was negated by the addition of quercetin mediated by
upregulation of DRs and downregulation the anti-apoptotic protein FLIP.

In the end, these data show the potential of rhTRAIL for the treatment of
rhTRAIL-sensitive malignant melanomas. A treatment that would be far superior to
traditional therapeutics in terms of tolerability. However, for malignant melanomas
resistant to rhTRAIL, the addition of quercetin in a combination treatment can sensitive
the resistance cells to the effects of rhTRAIL.
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